Published Scientific Research

The International Hyperhidrosis Society was founded in 2003 by a group of dedicated physicians and medical professionals with a commitment to scientific rigor in hyperhidrosis and related fields. As part of that commitment, we keep an extensive inventory of published scientific literature relevant to hyperhidrosis and share it with you, here. We believe it's vital to review published clinical data whenever discussing or reporting on health and hyperhidrosis and we strongly encourage product and treatment development teams to conduct rigorous testing and to espouse only that which can be validated.

Below you will find chronological links to articles, posters, and study data representing the most current peer-reviewed medical and scientific information available on the physiology, treatment, and effects of hyperhidrosis. New data will be posted as it becomes available. Use this rich library of research to inform your decisions and perceptions.

Are you working on research in hyperhidrosis? We can help in many ways!

Want to provide a grant to support hyperhidrosis research? Just send an email to our Executive Director, Lisa J. Pieretti via our Contact Us form.

And, as always, your donations are vital to our continued, collective work toward better care, improved lives, and greater understanding.

We do our best to scour all publications and post hyperhidrosis research here, but if we have missed something, please let us know. We will be happy to include it!

 

2024 studies

Abdel Azim S, Whiting C et al. Primary hyperhidrosis: an update on epidemiology and disease severity. Poster presented at American Academy of Dermatology Annual Meeting; March 8-12, 2024; San Diego, CA.

Alhudaif, Ali et al. “Facial Apocrine Chromhidrosis: A Case Report.” Cureus vol. 16,2 e53401. 1 Feb. 2024, doi:10.7759/cureus.53401

Whiting C, McCormick E et al. Primary hyperhidrosis and sensitive skin syndrome:  a national pilot survey. Poster presented at American Academy of Dermatology Annual Meeting; March 8-12, 2024; San Diego, CA.

2023 studies

Albucker SJ, Lipner SR. Microwave energy devices for hyperhidrosis are associated with infections, neurologic symptoms, and burns in a retrospective analysis of the Manufacturer and User Facility Device Experience database 2013-2022 [published online ahead of print, 2023 Jun 7]. J Am Acad Dermatol. 2023;S0190-9622(23)01015-0. doi:10.1016/j.jaad.2023.06.005

Fujimoto T, Terahara T, Okawa K, Inakura H, Hirayama Y, Yokozeki H. A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study. J Am Acad Dermatol. 2023;89(1):62-69. doi:10.1016/j.jaad.2023.03.025 (Abstract Only)

Glaser D, Green L, Kaminer M, Smith S, Pariser D. Outcomes from the SAHARA clinical study on the TAT patch for excessive axillary sweating or primary axillary hyperhidrosis. Poster presented at the Music City SCALE 2023; May 17-21, 2023; Nashville, TN.

Han JW, Ahn S, Jeong JY, Park CB, Eom E, Park SS. Use of thoracoscopy for thoracic sympathetic nerve block in primary hyperhidrosis. Sci Rep. 2023;13(1):1402. Published 2023 Jan 25. doi:10.1038/s41598-023-28727-5

Jacob C, Day D. Primary axillary hyperhidrosis or excessive axillary sweating in aesthetics patients: prevalent, mostly undiagnosed, embarrassing, impairs quality of life, demonstrates need for new treatment. Poster presented at the Cosmetic Bootcamp Summer Meeting 2023; June 22-25, 2023; Aspen, CO.

Jacob C, Green L. Quality of life improvement shown during SAHARA clinical study on the TAT patch for the treatment of primary axillary hyperhidrosis or excessive axillary sweating. Poster presented at the Cosmetic Bootcamp Summer Meeting 2023; June 22-25, 2023; Aspen, CO.

Kravitz SA, Lannan FM, Simpson MM. Long-term Effectiveness of Microwave Thermoablation in Persons With Residual Limb Hyperhidrosis: A Case Series. Mil Med. 2023;188(1-2):e417-e420. doi:10.1093/milmed/usab083 (Abstract Only)

Oshima Y, Fujimoto T, Nomoto M, Fukui J, Ikoma A. Hyperhidrosis: A targeted literature review of the disease burden [published online ahead of print, 2023 Jul 31]. J Dermatol. 2023;10.1111/1346-8138.16908. doi:10.1111/1346-8138.16908 (Abstract Only)

Parashar K, Adlam T, Potts G. The Impact of Hyperhidrosis on Quality of Life: A Review of the Literature. Am J Clin Dermatol. 2023;24(2):187-198. doi: 10.1007/s40257-022-00743-7

Ravendran K, Babu B, Madouros N, Panagiotopoulos N. Robotic Sympathectomy for Hyperhidrosis. Cureus. 2023;15(1):e33885. Published 2023 Jan 17. doi:10.7759/cureus.33885

Rocha Melo J, Rodrigues MA, Caetano M, Cantista P. Botulinum toxin in the treatment of residual limb hyperhidrosis: A systematic review [published online ahead of print, 2023 Feb 13]. Rehabilitacion (Madr). 2023;57(3):100754. doi:10.1016/j.rh.2022.07.003 (Abstract Only)

Saki N, Shakouri N, Rastaghi F, Hosseini SA, Alipour S, Ahramiyanpour N. Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double-blind randomized controlled trial. J Cosmet Dermatol. 2023;22(8):2268-2272. doi:10.1111/jocd.15715

Szeimies RM, Abels C, Kilic A, et al. Long-term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial [published online ahead of print, 2023 Jan 6]. J Eur Acad Dermatol Venereol. 2023;10.1111/jdv.18843. doi:10.1111/jdv.18843

Taudorf EH, Henning M, Olsen J, Thorlacius L, Christensen R, Jemec G. Attempted treatment of primary axillary hyperhidrosis with one session of either Neodymium YAG laser or Intense Pulsed Light: A within patient randomized trial of treated versus untreated contralateral axilla. Lasers Surg Med. 2023;55(8):748-757. doi:10.1002/lsm.23697 (Abstract Only)

Whiting C, McCormick E et al. Primary hyperhidrosis and sensitive skin syndrome:  a national pilot survey. Poster presented at American Academy of Dermatology Annual Meeting; March 8-12, 2024; San Diego, CA.

Wilkes, Dustin. and Shivaraj Nagalli. “Chromhidrosis.” StatPearls, StatPearls Publishing, 3 July 2023.

2022 studies

Ando Y, Ohshima Y, Yanagishita T, et al. Clinical utility of botulinum toxin type A local injection therapy for head and forehead hyperhidrosis. J Dermatol. 2022;49(7):719-723. doi:10.1111/1346-8138.16368 (Abstract Only)

Chudry H. The treatment of palmar hyperhidrosis - a systematic review. Int J Dermatol. 2022;61(11):1303-1310. doi:10.1111/ijd.15937

Collercandy N, Thorey C, Diot E, et al. When to investigate for secondary hyperhidrosis: data from a retrospective cohort of all causes of recurrent sweating. Ann Med. 2022;54(1):2089-2101. doi:10.1080/07853890.2022.2102675

de Campos AM, Silva RR, Calegaro ML, Raymundo-Pereira PA. Design and Fabrication of Flexible Copper Sensor Decorated with Bismuth Micro/Nanodentrites to Detect Lead and Cadmium in Noninvasive Samples of Sweat. Chemosensors. 2022; 10(11):446. doi.org/10.3390/chemosensors10110446

Ebrahim H, Nassar A, Mousa MM, Khater E. Microneedling Delivery of Botulinum Toxin Versus Intradermal Injection in the Treatment of Facial Hyperhidrosis. J Clin Aesthet Dermatol. 2022;15(9):40-44. (Abstract Only)

Fujimoto T, Okatsu H, Miyama H. Two-week prospective observational study of 5% sofpironium bromide gel in Japanese patients with primary axillary hyperhidrosis [published correction appears in J Dermatol. 2022 Aug;49(8):800]. J Dermatol. 2022;49(6):594-599. doi:10.1111/1346-8138.16384

Gregoriou S, Tsiogka A, Kontochristopoulos G, Offidani A, Campanati A. Sofpironium bromide: an investigational agent for the treatment of axillary hyperhidrosis. Expert Opin Investig Drugs. 2022;31(1):15-21. doi:10.1080/13543784.2022.2017880 (Abstract Only)

Heiskanen SL, Niskala J, Jokelainen J, Tasanen K, Huilaja L, Sinikumpu SP. Hyperhidrosis Comorbidities and Treatments: A Register-based Study among 511 Subjects. Acta Derm Venereol. 2022;102:adv00656. Published 2022 Feb 28. doi:10.2340/actadv.v102.1061

Henning MAS, Ibler KS, Loft I, et al. The health-related quality of life in hyperhidrosis and co-morbidities. Qual Life Res. 2022;31(8):2331-2340. doi:10.1007/s11136-022-03108-z (Abstract Only)

Jung JM, Na HM, Kim JH, et al. The efficacy and safety of a fractional microneedle radiofrequency device for the treatment of axillary hyperhidrosis: clinical prospective pilot study. Lasers Med Sci. 2022;37(3):1559-1566. doi:10.1007/s10103-021-03404-z (Abstract Only)

Kaufman J, Green JB, Cazzaniga A, Canty DJ, Tims E, Waugh J. A Pilot Study of the Safety and Effectiveness of a Novel Device in Subjects With Axillary Hyperhidrosis. Dermatol Surg. 2022 Nov 1;48(11):1220-1225. doi: 10.1097/DSS.0000000000003598. Epub 2022

Kotitsas P, Tsiogka A, Agiasofitou E, et al. Residual limb hyperhidrosis successfully managed with topical glycopyrrolate. Indian J Dermatol Venereol Leprol. 2022;88(2):230-231. doi:10.25259/IJDVL_132_2021

Kristensen JK, Nielsen C. Decreased work productivity due to primary palmar hyperhidrosis. What is the cost?. Skin Health Dis. 2021;1(2):e24. Published 2021 Apr 5. doi:10.1002/ski2.24

Kristensen JK, Nielsen C. Progress and lack of progress in hyperhidrosis research 2015-2020. A concise systematic review. Int J Dermatol. 2022;61(2):148-157. doi:10.1111/ijd.15654 (Abstract Only)

Lee DG, Kim JE, Lee WS, et al. A Phase 3, Randomized, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Neu-BoNT/A in Treatment of Primary Axillary Hyperhidrosis. Aesthetic Plast Surg. 2022;46(3):1400-1406. doi:10.1007/s00266-021-02715-4 (Abstract Only)

J. Lin, R. Ou, Q. Wei, B. Cao, C. Li, Y. Hou, L. Zhang, K. Liu, H. Shang. Hyperhidrosis in Parkinson's disease: a 3-year prospective cohort study. Journal of The European Academy of Dermatology and Venereology (JEADV). 13 March 2022; https://doi.org/10.1111/jdv.18072

Nofal E, Salem S, Khashaba SA. Intradermal Botulinum Toxin A Injection Versus Topical 2% Glycopyrrolate for the Treatment of Primary Facial Hyperhidrosis: A Pilot Study and Review of Literature. Dermatol Surg. 2022;48(8):843-848. doi:10.1097/DSS.0000000000003490 (Abstract Only)

 

Pitliuk R, Coelho CMF, Fucci TPPDCS. Unexpected improvement of hyperhidrosis with cannabidiol. Einstein (Sao Paulo). 2022;20:eRC5795. Published 2022 Feb 8. doi:10.31744/einstein_journal/2022RC5795

Raveglia F, Orlandi R, Guttadauro A, et al. How to Prevent, Reduce, and Treat Severe Post Sympathetic Chain Compensatory Hyperhidrosis: 2021 State of the Art. Front Surg. 2022;8:814916. Published 2022 Jan 3. doi:10.3389/fsurg.2021.814916

Shih T, Lee K, Seivright JR, De DR, Shi VY, Hsiao JL. Hyperhidrosis treatments in hidradenitis suppurativa: A systematic review. Dermatol Ther. 2022;35(1):e15210. doi:10.1111/dth.15210

Woo W, Oh J, Kim BJ, Won J, Moon DH, Lee S. The Impact of COVID-19 on Hyperhidrosis Patients in the Mental Health and Quality of Life: A Web-Based Surveillance Study. J Clin Med. 2022;11(13):3576. Published 2022 Jun 21. doi:10.3390/jcm11133576

Zhang D, Zhuang W, Lan Z, et al. Long-term follow-up in quality of life before and after endoscopic thoracic sympathicotomy in 367 patients with palmar hyperhidrosis. Ann Palliat Med. 2022;11(6):1961-1968. doi:10.21037/apm-21-2860 (Abstract Only)

Zhang Y, Gong YY, Tang YL, et al. Clinical efficacy of microwave in the treatment of axillary osmidrosis and primary hyperhidrosis. Dermatol Ther. 2022;35(8):e15657. doi:10.1111/dth.15657 (Abstract Only)

2021 studies

Abels C, Soeberdt M, Kilic A, et al. A 1% glycopyrronium bromide cream for the topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase 3a randomised controlled study [published online ahead of print, 2021 Jan 14]. Br J Dermatol. 2021;10.1111/bjd.19810. doi:10.1111/bjd.19810

Chang TN, Daniel BW, Hsu AT, et al. Reversal of thoracic sympathectomy through robot-assisted microsurgical sympathetic trunk reconstruction with sural nerve graft and additional end-to-side coaptation of the intercostal nerves: A case report. Microsurgery. 2021;41(8):772-776. doi:10.1002/micr.30787 (Abstract Only)

Chen LW, Goh M, Goh R, et al. Robotic-Assisted Peripheral Nerve Surgery: A Systematic Review. J Reconstr Microsurg. 2021;37(6):503-513. doi:10.1055/s-0040-1722183 (Abstract Only)

Ezure T, Amano S, Matsuzaki K. Aging-related shift of eccrine sweat glands toward the skin surface due to tangling and rotation of the secretory ducts revealed by digital 3D skin reconstruction. Skin Res Technol. 2021;27(4):569-575. doi:10.1111/srt.12985 (Abstract Only)

Fujimoto T, Abe Y, Igarashi M, et al. A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis [published online ahead of print, 2021 May 26]. J Dermatol. 2021;10.1111/1346-8138.15927. doi:10.1111/1346-8138.15927  

Gregoriou S, Campanati A, Rigopoulos D, Maria Offidani A, Stratigos A, Kontochristoulos G. Investigational topical anticholinergics in clinical development for the treatment of hyperhidrosis. Expert Opin Investig Drugs. 2021;30(5):479-482. doi:10.1080/13543784.2021.1900114 (Abstract Not Available)

Gregoriou S, Kontochristopoulos G, Tiligada E. Pharmacokinetic profile data of glycopyrronium bromide 1% cream beyond 2 weeks are important. Br J Dermatol. 2021;185(2):467-468. doi:10.1111/bjd.20088 (Abstract Not Available)

Gregoriou S, Markantoni V, Campanati A, et al. Treatment of Axillary Bromhidrosis with Topical 2% Glycopyrronium Bromide Cream: A Prospective, Non-randomized, Open-label Study. J Clin Aesthet Dermatol. 2021;14(11):E61-E63.

Hur, K.J., Moon, H.W., Park, Y.H. et al. Retroperitoneoscopic lumbar sympathectomy for the treatment of primary plantar hyperhidrosis. BMC Surg 21, 397 (2021). https://doi.org/10.1186/s12893-021-01393-y

Kataoka A, Mendes CCS. Psychological implications for patients with bromhidrosis. Rev. Bras. Cir. Plást. 2021;36(4):443-450.

Kirsch B, DuBois J, Zaiac M, Ahuja S, Chadha D.  A multi-center, open-label extension study to assess the long-term safety, tolerability and pharmacokinetics, and explore the efficacy of sofpironium bromide gel, 15% applied topically to children and adolescents, 9 to 16 years of age, with primary axillary hyperhidrosis (BBI-4000-CL-108).  Poster presented virtually at the 2021 Masters of Pediatric Dermatology conference; February 4-5, 2021. 

Kontochristopoulos G, Markantoni V, Agiasofitou E, et al. Treatment of primary axillary hyperhidrosis with a cream formulation of oxybutynin chloride 10. J Eur Acad Dermatol Venereol. 2021;35(8):e524-e526. doi:10.1111/jdv.17297 (Abstract Not Available) 

Lannan FM, Powell J, Kim GM, Hansen CR, Pasquina PF, Smith DG. Hyperhidrosis of the residual limb: a narrative review of the measurement and treatment of excess perspiration affecting individuals with amputation. Prosthet Orthot Int. 2021;45(6):477-486. doi:10.1097/PXR.0000000000000040 (Abstract Only)

Malik AS, Porter CL, Feldman SR. Bromhidrosis Treatment Modalities: A Literature Review [published online ahead of print, 2021 Jan 19]. J Am Acad Dermatol. 2021;S0190-9622(21)00175-4. doi:10.1016/j.jaad.2021.01.030 (Abstract Only)

Pariser DM, Lain EL, Mamelok RD, Drew J, Mould DR. Limited systemic exposure with topical glycopyrronium tosylate in primary axillary hyperhidrosis [published online ahead of print, 2021 Jan 12]. Clin Pharmacokinet. 2021;10.1007/s40262-020-00975-y.  doi:10.1007/s40262-020-00975-y

Park HH, Conic RR, Zhang S, Lieu A, Haft M, Hightower GK.  Oral glycopyrrolate for primary focal hyperhidrosis in pediatric population:  a cross-sectional study [published online ahead of print, 2021 July].  JAAD International 4 (2021):  65-66.  doi:  10.1016/j.jdin.2021.07.002

Remington C, Ruth J, Hebert AA. Primary hyperhidrosis in children: A review of therapeutics [published online ahead of print, 2021 Mar 4]. Pediatr Dermatol. 2021;10.1111/pde.14551. doi:10.1111/pde.14551 (Abstract Only)  

Rice ZP, Sidbury R, Pieretti LJ, Devlin T, Gillard KK, Comoroda D, Kosinski M, Hebert AA.  Hyperhidrosis affects multiple focal areas and is undertreated in pediatric sufferers:  survey results from population of > 500 children and adolescents (ages 6-18).  Poster presented virtually at the 19th Annual South Beach Symposium; February 4-7, 2021.  

Rice ZP, Sidbury R, Pieretti LJ, Devlin T, Gillard KK, Comoroda D, Kosinski M, Hebert AA.  Hyperhidrosis awareness and treatment in pediatric sufferers: survey results from a population of >500 children and adolescents (Ages 6-18). Poster presented virtually at the 42nd Annual Conference of the National Association of Pediatric Nurse Practitioners; March 24-27, 2021.

Rice ZP, Pieretti LJ, Wheeler A, Payne J, Gillard KK, Devlin T, Sidbury R, Hebert AA. Clinical presentation and quality of life burden associated with hyperhidrosis in children and adolescents (ages 6-18) and young adults (ages 18-30). Poster presented virtually at the 2021 Society for Adolescent Health & Medicine Annual Meeting; March 10-12, 2021.

Sandhaus T, Steinert M, Doenst T.  Bilateral robot-assisted thoracic sympathectomy for hyperhidrosis. Thorac Cardiovasc Surg. 2021;69:S1-S85. doi: 10.1055/s-0041-1725784 (Abstract Only)

Shayesteh A, Persson M, Brulin C, Nylander E. 'Excessive sweating is not a feminine thing': A qualitative study of women's experiences suffering from primary hyperhidrosis. PLoS One. 2021;16(7):e0254689. Published 2021 Jul 15. doi:10.1371/journal.pone.0254689

Starling CT, Nguyen QD, Butler IJ, Numan MT, Hebert AA. Cutaneous manifestations of orthostatic intolerance syndromes. Int J Womens Dermatol. 2021;7(4):471-477. Published 2021 Mar 11. doi:10.1016/j.ijwd.2021.03.003

Toolabi K, Khaki S, Sadeghian E, Lamsehchi N, Elyasinia F.  The rate of compensatory sweating and clinical outcomes of selective thoracoscopic sympathectomy (ramicotomy) in patients with primary palmar hyperhidrosis. Arch Neurosci. 2021;8(1):e111026.  doi: 10.5812/ans.111026

Vanaclocha V, Guijarro-Jorge R, Saiz-Sapena N, et al. Selective T3-T4 sympathicotomy versus gray ramicotomy on outcome and quality of life in hyperhidrosis patients: a randomized clinical trial. Sci Rep. 2021;11(1):17628. Published 2021 Sep 2. doi:10.1038/s41598-021-96972-7

Yokozeki H, Fujimoto T, Abe Y, et al. A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis [published online ahead of print, 2021 Jan 7]. J Dermatol. 2021;10.1111/1346-8138.15668. doi:10.1111/1346-8138.15668

2020 studies

Campanati A, Gregoriou S, Consales V, et al. Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results of a clinical, multicenter, prospective study. Dermatol Ther. 2020;33(6):e14039. doi:10.1111/dth.14039 (Abstract Only)

Caserta F, Lenn J, Hofland H. Variables affecting delivery of glycopyrronium tosylate through human skin in vitro. J Drugs Dermatol. 2020;19(11):1080-1085. doi:10.36849/JDD.2020.5062

Chang TN, Chen LW, Lee CP, Chang KH, Chuang DC, Chao YK. Microsurgical robotic suturing of sural nerve graft for sympathetic nerve reconstruction: a technical feasibility study. J Thorac Dis. 2020;12(2):97-104. doi:10.21037/jtd.2019.08.52

Dogru MV, Sezen CB, Girgin O, et al. Is there any relationship between quality of life and the level of sympathectomy in primary palmar hyperhidrosis? Single-center experience. Gen Thorac Cardiovasc Surg. 2020;68(3):273-279. doi:10.1007/s11748-019-01210-7 (Abstract Only)

Gabes M, Jourdan C, Schramm K, Masur C, Abels C, Kamudoni P, Salek S & Apfelbacher C.  Hyperhidrosis quality of life index (HidroQol©):  further validation and clinical application in patients with axillary hyperhidrosis using data from a phase III randomized controlled trial.  British Journal of Dermatology 2020.  doi:  10.1111/bjd.19300.

Gharagozloo F. Robotic selective thoracic sympathectomy for hyperhidrosis. Mini-invasive Surgery. 2020; 4:14.

Gharagozloo F, Meyer M, Tempesta B. Robotic Staged Bilateral Selective Postganglionic Sympathectomy for Upper-Extremity Hyperhidrosis. Surg Technol Int. 2020;36:265-269. (Abstract Only)

Gorelick J, Friedman A.  Diagnosis and management of primary hyperhidrosis:  practical guidance and current therapy update.  J Drugs Dermatol 19:7 (2020):  217-223.  doi:  10.36849/JDD.2020.5162. (Abstract Only)

Hebert AA, Glaser DA, Green L, et al. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study. Pediatr Dermatol. 2020;37(3):490-497. doi:10.1111/pde.14135

Kirsch B, Smith S, Cohen J, Liu PY, Chadha D, Walker P.  Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis:  a phase II, randomized, controlled, double-blinded trial.  J Am Acad Dermatol 82:6 (2020):  1321-1327.  doi:  10.1016/j.jaad.2020.02.016. (Abstract Only)

Klein SZ, Hull M, Gillard KK, Peterson-Brandt J. Treatment patterns, depression, and anxiety among US patients diagnosed with hyperhidrosis: a retrospective cohort study. Dermatol Ther (Heidelb). 2020;10(6):1299-1314. doi:10.1007/s13555-020-00439-y

Kristensen JK, Vestergaard DG, Swartling C, Bygum A. Association of Primary Hyperhidrosis with Depression and Anxiety: A Systematic Review. Acta Derm Venereol. 2020;100(1):adv00044. Published 2020 Jan 30. doi:10.2340/00015555-3393

Nawrocki S, Cha J. Botulinum toxin: Pharmacology and injectable administration for the treatment of primary hyperhidrosis. J Am Acad Dermatol. 2020;82(4):969-979. doi:10.1016/j.jaad.2019.11.042 (Abstract Only) 

Parrish C, Waldbaum B, Coleman D, et al. Microwave Thermolysis Reduces Generalized and Social Anxiety in Young Adults With Axillary Hyperhidrosis. Lasers Surg Med. 2020;52(9):842-847. doi:10.1002/lsm.23229 (Abstract Only)

Rice ZP, Pieretti LJ, Wheeler A, Payne J, Gillard KK, Devlin T, Hebert AA. Characterization of disease awareness and coping strategies in primary focal hyperhidrosis:  qualitative focus group results in children, adolescents, and young adults.  Poster presented virtually at the 45th Annual Meeting of the Society for Pediatric Dermatology July 2020.

Rice ZP, Pieretti LJ, Wheeler A, Payne J, Gillard KK, Devlin T, Hebert AA. Quality of life impact of primary focal hyperhidrosis:  qualitative focus group results in children, adolescents, and young adults.  Poster presented virtually at the 45th Annual Meeting of the Society for Pediatric Dermatology July 2020.

Rice ZP, Pieretti LJ, Wheeler A, Payne J, Gillard K, Devlin T, Hebert AA.  Quality of life impact and awareness of primary focal hyperhidrosis in children and adolescents.  Poster presented virtually at the Maui Derm Connect Nurse Practitioners and Physician Assistants Fall 2020 Conference September 2020. 

Rudden M, Herman R, Rose M, et al. The molecular basis of thioalcohol production in human body odour. Sci Rep 10:12500 (2020).  doi: 10.1038/s41598-020-68860-z

Rummaneethorn P, Chalermchai T. A comparative study between intradermal botulinum toxin A and fractional microneedle radiofrequency (FMR) for the treatment of primary axillary hyperhidrosis. Lasers Med Sci. 2020;35(5):1179-1184. doi:10.1007/s10103-020-02958-8 (Abstract Only)

Stuart ME, Strite SA, Gillard KK. A systematic evidence-based review of treatments for primary hyperhidrosis. J Drug Assess. 2020;10(1):35-50. Published 2020 Dec 24. doi:10.1080/21556660.2020.1857149

Trettin B, Hansen J, Bygum A. The impact of adolescents' everyday life experiences on their primary hyperhidrosis treatment - a qualitative study [published online ahead of print, 2020 Jul 22]. J Dermatolog Treat. 2020;1-7. doi:10.1080/09546634.2020.1789541

Trindade de Almeida AR, Fonseca Noriega L, Bechelli L, Suarez MV.  Randomized controlled trial comparing the efficacy and safety of two injection techniques of incobotulinumtoxinA for axillary hyperhidrosis.  J Drugs Dermatol 19:7 (2020):  765-770.  doi:  10.36849/JDD.2020.4989. (Abstract Only)

Trindade de Almeida AR, Ferrari F, Restrepo MVS, Rocha VB. Oxybutynin in primary hyperhidrosis: A long-term real-life study. Dermatol Ther. 2020;33(6):e14344. doi:10.1111/dth.14344 (Abstract Only)

Wolosker N, Kauffman P, de Campos JRM, et al. Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases. Int J Dermatol. 2020;59(6):709-715. doi:10.1111/ijd.14872 (Abstract Only)

2019 studies

Cohen SR, Goodacre AK, Leong TS, Southwell L, Nomachi T. Short-Term Clinical Outcomes and Safety Associated With Percutaneous Radiofrequency Treatment for Excessive Sweating. Aesthet Surg J. 2019;39(12):1390-1399. doi:10.1093/asj/sjy277 (Abstract Only)

Dobosz L, Stefaniak T. Evaluation of Quality of Life: Functional Assessment of Chronic Illness Therapy after Thoracic Sympathectomy for Palmar Hyperhidrosis. Thorac Cardiovasc Surg. 2019;67(5):420-424. doi:10.1055/s-0038-1642029 (Abstract Only)

Gibbons M, Armbrecht E, Glaser DA. Primary axillary hyperhidrosis: do gravimetric measurements of sweat production correlate with disease severity or patient characteristic? Poster presented at the 77th Annual Meeting of the American Academy of Dermatology; March 1-5, 2019; Washington, DC.

Gollins CE, Carpenter A, Steen C, Bulinski H, Mahendran R. A retrospective analysis of the use of tap water iontophoresis for focal hyperhidrosis at a district general hospital: the patients' perspective. J Dermatolog Treat. 2019 Jan 16:1-9. doi: 10.1080/09546634.2019.1569751. (Abstract Only)

Glaser DA, Green L, Drew J, Gopalan R, Pariser DM. Topical glycopyrronium tosylate improves axillary hyperhidrosis across a broad spectrum of patients: post hoc analyses of the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials in patient subpopulations. Poster presented at the 77th Annual Meeting of the American Academy of Dermatology; March 1-5, 2019; Washington, DC.

Glaser DA, Hebert AA, Nast A, et al.  A 44-week open-label study evaluating safety and efficacy of topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis. Am J Clin Dermatol 20 (2019):  593-604.

Glaser EN, Armbrecht ES, King R, Glaser DA. Prevalence of anxiety, depression and attention deficit disorder (ADD) in patients with primary hyperhidrosis. Poster presented at the 77th Annual Meeting of the American Academy of Dermatology; March 1-5, 2019; Washington, DC.

Gregoriou S, Sidiropoulou P, Kontochristopoulos G, Rigopoulos D. Management Strategies Of Palmar Hyperhidrosis: Challenges And Solutions. Clin Cosmet Investig Dermatol. 2019;12:733-744. Published 2019 Oct 4. doi:10.2147/CCID.S210973

Hajjar WM, Al-Nassar SA, Al-Sharif HM, et al.  The quality of life and satisfaction rate of patients with upper limb hyperhidrosis before and after bilateral endoscopic thoracic sympathectomy. Saudi J Anaesth. 2019 Jan-Mar;13(1):16-22. doi: 10.4103/sja.SJA_335_18.

Hebert AA, Glaser DA, Ballard AM, Pieretti LJ, Pariser DM. Voice of the hyperhidrosis patient:   symptoms, impacts and treatments. Insights from large, open, FDA-attended meeting. Poster presented at the 77th Annual Meeting of the American Academy of Dermatology; March 1-5, 2019; Washington, DC.

Kanni T, Agiasofitou E, Markantoni V, et al. Cryoanalgesia with a CoolSense Device in Patients Treated with Botulinum Toxin-A for Palmar-Plantar Hyperhidrosis: A Self-Controlled Study. Skin Appendage Disord. 2019;5(2):119-120. doi:10.1159/000492239

Lain EL, Glaser DA, Gopalan R, Yan V, Drew J, Pariser DM. Long-term response with topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis according to double-blind treatment group. Poster presented at the 77th Annual Meeting of the American Academy of Dermatology; March 1-5, 2019; Washington, DC.

Nawrocki S, Cha J. The etiology, diagnosis and management of hyperhidrosis: a comprehensive review. Part II. Therapeutic options. J Am Acad Dermatol. 2019 Jan 30. pii: S0190-9622(19)30167-7. doi: 10.1016/j.jaad.2018.11.066. (Abstract Only)

Nawrocki S, Cha J. The etiology, diagnosis and management of hyperhidrosis: a comprehensive review. Part I. Etiology and clinical work-up. J Am Acad Dermatol. 2019 Jan 30. pii: S0190-9622(19)30168-9. doi: 10.1016/j.jaad.2018.12.07. (Abstract Only)

Nawrocki S, Cha J.  The etiology, diagnosis, and management of hyperhidrosis:  a comprehensive review:  etiology and clinical work-up.  Journal of the American Academy of Dermatology 81:3 (2019):  657-666.   

Nawrocki S, Cha J.  The etiology, diagnosis, and management of hyperhidrosis:  a comprehensive review:  therapeutic options.  Journal of the American Academy of Dermatology 81:3 (2019):  669-680. 

Pariser DM, Drew J, Gopalan R, Hebert AA. An evaluation of anticholinergic adverse events with long-term use of topical glycopyrronium tosylate, a treatment for primary axillary hyperhidrosis. Poster presented at the 77th Annual Meeting of the American Academy of Dermatology; March 1-5, 2019; Washington, DC.

Ribeiro Santos Morard M, Betanho Martins R, Lopes Ribeiro AC, Guimarães Rocha Lima P, Dos Santos Carvalho B, Junior JCBS. Primary hyperhidrosis prevalence and characteristics among medical students in Rio de Janeiro. PLoS One. 2019;14(9):e0220664. Published 2019 Sep 13. doi:10.1371/journal.pone.0220664

Scotelaro-Alves HG, Fernandes NC, Ramos-E-Silva M. Clinical profile of recurrent vesicular palmoplantar dermatitis in children and adolescents. Clin Cosmet Investig Dermatol. 2019 Jan 3;12:23-28. doi: 10.2147/CCID.S150778.

Schreiner W, Mykoliuk I, Dudek W, Sirbu H. Impact of selective quality of life analysis in patients with local hyperhidrosis after sympathicus clipping. Zentralbl Chir. 2019 Feb 22. doi: 10.1055/a-0808-5003 (Abstract Only)

Shayesteh A, Brulin C, Nylander E. The Meaning of Living for Men Suffering From Primary Hyperhidrosis. Am J Mens Health. 2019;13(6):1557988319892725. doi:10.1177/1557988319892725

Shim DH, Nguyen TT, Park PG, et al. Development of Botulinum Toxin A-Coated Microneedles for Treating Palmar Hyperhidrosis. Mol Pharm. 2019;16(12):4913-4919. doi:10.1021/acs.molpharmaceut.9b00794 (Abstract Only)

Sidiropoulou P, Gregoriou S, Balaskas E, et al. Managing pitted keratolysis through hyperhidrosis control with topical glycopyrrolate 2%. Poster presented at the 77th Annual Meeting of the American Academy of Dermatology; March 1-5, 2019; Washington, DC.

Trindade de Almeida AR, Rocha de Moura Moreira V, Ferrari F.  Topical and systemic anticholinergic for treating hyperhidrosis.  Shanghai Chest2019.  doi:  10.21037/shc.2019.07.02.    

Wechter T, Feldman SR, Taylor SL. The Treatment of Primary Focal Hyperhidrosis. Skin Therapy Lett. 2019;24(1):1-7.

2018 studies

Akil A, Semik M, Fischer S. Efficacy of miniuniportal video-assisted thoracoscopic selective sympathectomy (ramicotomy) for the treatment of severe palmar and axillar hyperhidrosis. Thorac Cardiovasc Surg. 2018 May 8. doi:  10.1055/s-0038-1642030. (Abstract Only)

Bernhard MK, Krause M, Syrbe S. Sweaty feet in adolescents-early use of botulinum type A toxin in juvenile plantar hyperhidrosis. Pediatr Dermatol. 2018 Nov;35(6):784-786. doi: 10.1111/pde.13628. (Abstract Only)

Chilukuri S, Robb CW, Weiner SF, Grossman J. Primary Axillary Hyperhidrosis Treatment Using High Intensity Focused Fractional Radiofrequency Microneedling. J Drugs Dermatol. 2018;17(7):745-748. (Abstract Only)

Cohen SR, Goodacre AK, Leong TS, Southwell L, Nomachi T. Short-term clinical outcomes and safety associated with percutaneous radiofrequency treatment for excessive sweating. Aesthet Surg J. 2018 Dec 9. doi: 10.1093/asj/sjy277. (Abstract Only)

Eustace K, Wilson NJ. Postmenopausal craniofacial hyperhidrosis. Clin Exp Dermatol. 2018 Mar;43(2):180-182. doi: 10.1111/ced.13310.

Glaser DA, Hebert AA, Nast A, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2019 Jan;80(1):128-138.e2. doi: 10.1016/j.jaad.2018.07.002. Epub 2018 Jul 10.

Glaser DA, Hebert A, Pieretti L, Pariser D. Understanding Patient Experience with Hyperhidrosis: A National Survey of 1,985 Patients. Journal of Drugs in Dermatology 2018 17(4):392-396.

Glaser D et al.  Open-label study evaluating long-term safety of topical glycopyrronium tosylate (GT) in patients with primary axillary hyperhidrosis (ARIDO).  Presented at the 76th Annual Meeting of the American Academy of Dermatology February 2018.

Hasimoto EN, Cataneo DC, Reis TAD, Cataneo AJM. Hyperhidrosis: prevalence and impact on quality of life. J Bras Pneumol. 2018;44(4):292-298. doi:10.1590/S1806-37562017000000379

Hebert AA, Glaser DA, Green L, et al. Short- and long-term efficacy and safety of glycopyrronium cloth for the treatment of primary axillary hyperhidrosis: post hoc pediatric subgroup analyses from the phase 3 studies. Presented at the 37th Fall Clinical Dermatology Conference October 2018.

Hebert A et al.  Glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis:  pediatric subgroup analyses from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.  Presented at the 76th Annual Meeting of the American Academy of Dermatology February 2018.

Hebert AA, Glaser DA, Green L, et al. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
Pediatr Dermatol. 2018;00:1-11. doi: 10.1111/pde.13723.

Horslen LC, Wilshire CL, Louie BE, Vallières E. Long-Term Impact of Endoscopic Thoracic Sympathectomy for Primary Palmar Hyperhidrosis. Ann Thorac Surg. 2018 Oct;106(4):1008-1012. doi: 10.1016/j.athoracsur.2018.04.063. Epub 2018 Jun 7. (Abstract Only) 

Jacob CI. Examining hyperhidrosis: an update on new treatments. Am J Manag Care. 2018 Dec;24(23 Suppl):S496-S501.

Leiderman DB, Yazbec G, Wolosker N.  Management of compensatory hyperhidrosis.  Hyperhidrosis.  de Paula Loureiro M, de Campos JR, Wolosker N, Kauffman P (ed):  Springer International Publishing, Cham; 2018.  197-202.  doi: 10.1007/978-3-319-89527-7_26 (Abstract Only)

Li DC, Hulbert A, Waldbaum B, et al. Endoscopic thoracic sympathectomy for primary focal hyperhidrosis: impact on psycho-social symptomatology and psychotropic medication use. Eur J Cardiothorac Surg. 2018;54(5):904-911. doi:10.1093/ejcts/ezy211

Lenefsky M, Rice ZP. Hyperhidrosis and its impact on those living with it. Am J Manag Care. 2018 Dec;24(23 Suppl):S491-S495.

Lubarda J, Dermer S, Maeglin J, Young M, Pariser D. Current management of hyperhidrosis: how do NPs and PAs perform? Presented at the Dermatology Education Foundation 2018 DERM July 2018.

Lubarda J, Dermer S, Maeglin J, Young M, Pariser D. Hyperhidrosis clinical practice patterns and barriers: how do physicians perform? Presented at the 27th European Academy of Dermatology and Venereology Congress September 2018.

López-López D, Becerro-de-Bengoa-Vallejo R, Losa-Iglesias ME, Rodríguez-Sanz D, Palomo-López P, Calvo-Lobo C. Relationship between depression scores and degree of skin perspiration: A novel cross-sectional study. Int Wound J. 2019 Feb;16(1):139-143. doi: 10.1111/iwj.13004.

McConaghy JR, Fosselman D. Hyperhidrosis: management options. Am Fam Physician. 2018;97(11):729-734.

Mirkovic SE, Rystedt A, Balling M, Swartling C. Hyperhidrosis Substantially Reduces Quality of Life in Children: A Retrospective Study Describing Symptoms, Consequences and Treatment with Botulinum Toxin. Acta Derm Venereol. 2018;98(1):103-107. doi:10.2340/00015555-2755 (Abstract Only)

Pariser DM, Hebert AA, Drew J, Quiring J, Gopalan R, Glaser DA. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis:  patient-reported outcomes from the ATMOS-1 and ATMOS-2 phase III randomized controlled trials. Am J Clin Dermatol. 2018 Oct 30. doi:  10.1007/s40257-018-0395-0.

Pariser D et al.  Topical glycopyrronium tosylate (DRM04) for the treatment of primary axillary hyperhidrosis:  pooled results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.  Presented at the 76th Annual Meeting of the American Academy of Dermatology February 2018.

Pariser D et al.  Glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis:  prior treatment analyses from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.  Presented at the 76th Annual Meeting of the American Academy of Dermatology February 2018.

Simes BC, Moore JP, Brown TC, Rushforth TJ, Bookout AL, Richardson CL. Genetic polymorphism analysis of patients with primary hyperhidrosis. Clin Cosmet Investig Dermatol. 2018;11:477-483. Published 2018 Oct 11. doi:10.2147/CCID.S176842

Stern J, Zhu S, Blow I, Johnson D.  The efficacy of the BedJet Climate System® for peri-menopausal night sweat and hot flash symptoms and corresponding impact on sleep.  Presented at the 29th Annual Meeting of the North American Menopause Society; October 3-6, 2018; San Diego, CA.

Wade R, Llewellyn A, Jones-Diette J, et al. Interventional management of hyperhidrosis in secondary care: a systematic review. Br J Dermatol. 2018 Sep;179(3):599-608. doi:  10.1111/bjd.16558.

2017 studies

Artzi O, Loizides C, Zur E, Sprecher E. Topical Oxybutynin 10% Gel for the Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split Area Study. Acta Derm Venereol. 2017;97(9):1120-1124. doi:10.2340/00015555-2731

 

Dagash H, McCaffery S, Mellor K, Roycroft A, Helbling I. Tap water iontophoresis in the treatment of pediatric hyperhidrosis. J Pediatr Surg. 2017 Feb;52(2):309-312.

Elalfy K, Emile S, Elfeki H, Elmetwally A, Farag M, Gado W. Sequential Extended Thoracoscopic Sympathicotomy for Palmo-Axillo-Plantar Hyperhidrosis. Ann Thorac Surg. 2017;104(4):1200-1207. doi:10.1016/j.athoracsur.2017.04.035 (Abstract Only)

Glaser D et al.  Open-label study (ARIDO) evaluating long-term safety of topical glycopyrronium tosylate (GT) in patients with primary axillary hyperhidrosis.  Presented at the 36th Fall Clinical Dermatology Conference October 2017.

Grabell D, Hebert A. Current and Emerging Medical Therapies for Primary Hyperhidrosis. Dermatol Ther (Heidelb). 2017 Mar; 7(1): 25–36.

Hansen CR, Godfrey B. Residual Limb Hyperhidrosis Managed by Botulinum Toxin Injections, Enhanced by the Iodine-Starch Test: A Case Report. PM R. 2017;9(4):415-418. doi:10.1016/j.pmrj.2016.10.009 (Abstract Only)

Hebert A, Glaser DA, Ballard A, Pieretti L, Trindade de Almeida A, Pariser D. Prevalence of primary focal hyperhidrosis among teens 12-17 in US Population. Abstract (5192) presented at American Academy of Dermatology March 2017, Late-Breaking Research: Clinical Studies/Pediatric (F072).

Hsu TH, Chen YT, Tu YK, Li CN. A systematic review of microwave-based therapy for axillary hyperhidrosis. J Cosmet Laser Ther. 2017 Mar 10. doi: 10.1080/14764172.2017.1303168.

Kamudoni P, Mueller B, Halford J, Schouveller A, Stacey B, Salek MS. The impact of hyperhidrosis on patients' daily life and quality of life: a qualitative investigation. Health and Quality of Life Outcomes. 2017 15:121.

Kargi AB. Plantar Sweating as an Indicator of Lower Risk of Compensatory Sweating after Thoracic Sympathectomy. Thorac Cardiovasc Surg. 2017 Sep;65(6):479-483. doi: 10.1055/s-0036-1579680. Epub 2016 Apr 4. (Abstract Only)

Lima SO, de Santana VR, Valido DP, et al. Retroperitoneoscopic lumbar sympathectomy for plantar hyperhidrosis. J Vasc Surg. 2017;66(6):1806-1813. doi:10.1016/j.jvs.2017.05.126 (Abstract Only)

Millan-Cayetano JF, et al.  Initial study of transdermal oxybutynin for treating hyperhidrosis.  J Dermatol doi:  10.1111/1346-8138.13748.  Published online January 20, 2017.

Mula KN, Winston J, Pace S, Kentosh JB. Use of a Microwave Device for Treatment of Amputation Residual Limb Hyperhidrosis. Dermatol Surg. 2017;43(1):149-152. doi:10.1097/DSS.0000000000000837 (Abstract Not Available)

Pariser D, Krishnaraja J, Tremblay T, Rubison M, Love T, McGraw B. Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects with Primary Focal Hyperhidrosis. Journal of Drugs in Dermatology 2017 Feb 1;16(2): 127-132. 

Pariser D, Hebert A, Drew J, Quiring J, Glaser D.  Patient-reported outcomes from two randomized, double-blind, vehicle-controlled phase 3 trials in axillary hyperhidrosis (ATMOS-1 & ATMOS-2).  Presented at the 26th European Academy of Dermatology and Venereology Congress September 2017.

Pariser D et al. DRM04 for the treatment of primary axillary hyperhidrosis:  primary results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.  Poster 4834 presented at the 75th Annual Meeting of the American Academy of Dermatology March 2017.

Shayesteh A, Janlert U, Nylander E. Hyperhidrosis - Sweating Sites Matter: Quality of Life in Primary Hyperhidrosis according to the Sweating Sites Measured by SF-36. Dermatology. 2017;233(6):441-445. doi:10.1159/000486713 (Abstract Only)

Vannucci F, Araújo JA. Thoracic sympathectomy for hyperhidrosis: from surgical indications to clinical results. J Thorac Dis. 2017;9(Suppl 3):S178-S192. doi:10.21037/jtd.2017.04.04

2016 studies

Bahar R, Zhou P, Liu Y, Huang Y, Phillips A, Lee T, et al. The prevalence of anxiety and depression in patients with or without hyperhidrosis (HH). J Am Acad Dermatol 75:6 (2016):  1126-1133. 

Connery CP. Reconstruction of the Sympathetic Chain. Thorac Surg Clin. 2016;26(4):427-434. doi:10.1016/j.thorsurg.2016.06.007 (Abstract Only)

Cramer DW, Vitonis AF, Terry KL, Welch WR, et al. The association between talc use and ovarian cancer: a retrospective case-control study in two US states. Epidemiology. 2016 May;27(3):334-46. 

Cruddas L, Baker DM. Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review. J Eur Acad Dermatol Venereol. 2016 Dec 15. doi: 10.1111/jdv.14081.

del Boz J et al. Individualized Dosing of Oral Oxybutynin for the Treatment of Primary Focal Hyperhidrosis in Children and Teenagers. Pediatr Dermatol (2016) 33: 327–331.

Dharmaraj B, Kosai NR, Gendeh H, Ramzisham AR, Das S. A Prospective Cohort Study on Quality of Life after Endoscopic Thoracic Sympathectomy for Primary Hyperhidrosis. Clin Ter. 2016 May-Jun;167(3):67-71. doi: 10.7417/CT.2016.1928. (Abstract Only) 

Dias LI, Miranda EC, Toro IF, Mussi RK. Relationship between anxiety, depression and quality of life with the intensity of reflex sweating after thoracoscopic sympathectomy for treatment of primary hyperhidrosis. Rev Col Bras Cir. 2016;43(5):354-359. doi:10.1590/0100-69912016005013 (Abstract Only)

Doolittle J, Walker P, Mills T, et al. Hyperhidrosis:  an update on prevalence and severity in the United States.  Arch Dermatol Res doi:  10.1007/s00403-016-1697-9.  Published online October 15, 2016.

Glaser D, Ballard A, Hunt N, Pieretti L & Pariser D. Prevalence of multifocal primary hyperhidrosis and symptom severity over time: results of a targeted survey. Dermatol Surg 42:12 (2016): 1347-1353.

Hansen CR, Godfrey B. Residual Limb Hyperhidrosis Managed by Botulinum Toxin Injections, Enhanced by the Iodine-Starch Test: A Case Report. American Academy of Physical Medicine and Rehabilitation. 2016 Oct 22. pii: S1934-1482(16)31056-5.

Hynes CF, Marshall MB. Reversibility of Sympathectomy for Primary Hyperhidrosis. Thorac Surg Clin. 2016 Nov;26(4):421-426. doi: 10.1016/j.thorsurg.2016.06.006. Epub 2016 Aug 4. Review. (Abstract Only)  

Ismail D, Madhwapathi V, Ladoyanni E. Focal Hyperhidrosis Associated with Recurrent Urinary Tract Infections. Case Reports in Dermatological Medicine. 2016;2016:3842984.

Liu Y, Bahar R, Kalia S, Huang RY, Phillips A, Su M, et al.  Hyperhidrosis prevalence and demographical characteristics in dermatology outpatients in Shanghai and Vancouver.  PLoS One doi: 10.1371/journal.pone.0153719.  Published online April 22, 2016.

Muthusamy A, Gajendran R, Ponnan S, Thangavel D, Rangan V. A Study on the Impact of Hyperhidrosis on the Quality of Life among College Students. Journal of Clinical and Diagnostic Research: JCDR. 2016;10(6):CC08-CC10.

Overwhelming foot odor. J Fam Pract. 2016 January;65(1)

Owen K. Excessive Sweating: Are Patients Suffering Unnecessarily? The Journal for Nurse Practitioners, January 2016, Volume 12, Issue 1, 35–40

Pace S, Kentosh J. Managing residual limb hyperhidrosis in wounded warriors. Cutis. 2016;97(6):401-403.

Pariser D et al.  DRM04 for the treatment of axillary hyperhidrosis: primary results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.  Late Breaking News D3T01.1 presented at the 25th European Academy of Dermatology and Venereology Congress October 2016.

Pasquina PF, Perry BN, Alphonso AL, Finn S, Fitzpatrick KF, Tsao JW. Residual Limb Hyperhidrosis and RimabotulinumtoxinB: A Randomized Placebo-Controlled Study. Arch Phys Med Rehabil. 2016;97(5):659-664.e2. doi:10.1016/j.apmr.2015.12.027 (Abstract Only)

Risacher SL, McDonald BC, Tallman EF, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal adults. JAMA Neurol. doi:10.1001/jamaneurol.2016.0508. Published online April 18, 2016. 

Rystedt A, Brismar K, Aquilonius SM, Naver H, Swartling C.  Hyperhidrosis—an unknown widespread “silent” disorder.  J Neurol Neuromed 1:4 (2016):  25-33.   

Scaglione F. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice. Toxins (Basel). 2016;8(3):65. Published 2016 Mar 4. doi:10.3390/toxins8030065

Schick CH, Grallath T, Schick KS, Hashmonai M. Radiofrequency Thermotherapy for Treating Axillary Hyperhidrosis. Dermatol Surg. 2016;42(5):624-630. doi:10.1097/DSS.0000000000000703 (Abstract Only)

Shahram M, Hassan Ali M, Mohammad Javad B, Reza M: Up-to-date treatments of primary hyperhidrosis with focus on sympathectomy and sympathicotomy; a narrative review. Hosp Pract Res. 2016; 1:3-7. doi:10.20286/hpr-01013

Shayesteh A, Janlert U, Brulin C, Boman J, Nylander E. Prevalence and characteristics of hyperhidrosis in Sweden:  a cross-sectional study inthe general population.  Dermatology doi:  10.1159/000448032. 

Shi LL, Sargen MR, Chen SC, Arbiser JL, Pollack BP. Effective local anesthesia for onabotulinumtoxin A injections to treat hyperhidrosis associated with traumatic amputation. Dermatol Online J. 2016;22(6):13030/qt38b203d0. Published 2016 Jun 15. (Abstract Only)

Singh S, Kaur S, Wilson P. Early experience with endoscopic lumbar sympathectomy for plantar hyperhidrosis. Asian J Endosc Surg. 2016 May;9(2):128-34

Vlahovic TC. Plantar Hyperhidrosis: An Overview. Clin Podiatr Med Surg. 2016;33(3):441-451. doi:10.1016/j.cpm.2016.02.010 (Abstract Only)

Wolosker N, Milanez de Campos JR, Fukuda JM. Management of compensatory sweating after sympathetic surgery. Thorac Surg Clin. 2016;26(4):445-451. doi:10.1016/j.thorsurg.2016.06.009 (Abstract Only)

2015 studies

Abtahi-Naeini B, Naeini FF, Adibi N, Pourazizi M. Quality of life in patients with primary axillary hyperhidrosis before and after treatment with fractionated microneedle radiofrequency. J Res Med Sci. 2015;20(7):631-635. doi:10.4103/1735-1995.166196

Campbell NL, Boustani MA. Adverse cognitive effects of medications. Turning attention to reversibility. Invited commentary. JAMA Intern Med doi: 10.1001/jamainternmed.2014.7667. 

Gray, Shelly L PharmD, MS, et al. Cumulative use of strong anticholingerics and incident of dementia. JAMA Intern Med doi: 10.1001/jamainternmed.2014.7663. Published online January 26, 2015.

Hansen C et al. Incidence, severity, and impact of hyperhidrosis in people with lower-limb amputation. J Rehabil Res Dev. 2015;52(1):31–40.

Huang H, Hohler AD. The Dermatological Manifestations of Postural Tachycardia Syndrome: A Review with Illustrated Cases. Am J Clin Dermatol. 2015;16(5):425-430. doi:10.1007/s40257-015-0144-6 (Abstract Only)

Jeong JY, Park SS, Sim SB, et al. Prediction of compensatory hyperhidrosis with botulinum toxin A and local anesthetic. Clin Auton Res. 2015;25(4):201-205. doi:10.1007/s10286-015-0288-8 (Abstract Only)

Kouris A, Armyra K, Stefanaki C, Christodoulou C, Karimali P, Kontochristopoulos G. Quality of life and social isolation in Greek adolescents with primary focal hyperhidrosis treated with botulinum toxin type A: a case series. Pediatr Dermatol. 2015;32(2):226-230. doi:10.1111/pde.12480 (Abstract Only)

Lezanski-Gujda A, Bingham JL, Logemann NF. Botulinum toxin: An effective treatment for prosthesis-related hyperhidrosis in patients with traumatic amputations. Indian Dermatol Online J. 2015;6(1):1-3. doi:10.4103/2229-5178.148906

Lima SO et al. Research of primary hyperhidrosis in students of medicine of the State of Sergipe, Brazil. Anais Brasileiros de Dermatologia. 2015;90(5):661-665.

Ma C, Sivamani RK. Acupuncture as a Treatment Modality in Dermatology: A Systematic Review. J Altern Complement Med. 2015 Sep;21(9):520-9.

Nicholas R, Quddas A, Baker DM. Treatment of Primary Craniofacial Hyperhidrosis: A Systemic Review. Am J Clin Dermatol. 2015 Oct;16(5):361-70. doi: 10.1007/s40257-015-0136-6.

Rieger R, Pedevilla S, Lausecker J. Quality of life after endoscopic lumbar sympathectomy for primary plantar hyperhidrosis. World J Surg. 2015;39(4):905-911. doi:10.1007/s00268-014-2885-4 (Abstract Only)

Schollhammer M, Brenaut E, Menard-Andivot N, Pillette-Delarue M, et al. (2015). Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. British Journal of Dermatology, 173: 1163-1168. doi: 10.1111/bjd.13973

Torres E, Fauconneau A, Fougerouse A, Boralevi F. Unusual pattern of neonatal hyperhidrosis. BMJ Case Rep. 2015;2015:bcr2015213754. Published 2015 Dec 18. doi:10.1136/bcr-2015-213754

2014 studies

Baroncello JB, Baroncello LR, Schneider EG, Martins GG. Evaluation of quality of life before and after videothoracoscopic simpathectomy for primary hyperhidrosis. Rev Col Bras Cir. 2014;41(5):325-330. doi:10.1590/0100-69912014005005 (Abstract Only)

Bell D, Jedynak J, Bell R. Predictors of outcome following endoscopic thoracic sympathectomy. ANZ J Surg. 2014 Jan-Feb;84(1-2):68-72. doi: 10.1111/ans.12098. Epub 2013 Feb 21. (Abstract Only) 

Bohaty, Benjamin R. MD & Hebert, Adelaide A. MD. Special considerations for children with hyperhidrosis. Dermatologic Clinics 32:4 (2014): 477-484. 

Boschert S.  Laser therapy improved severe hyperhidrosis. Dermatology News, 30 April 2014.  

Caplin D, Austin J. Clinical evaluation and quantitative analysis of axillary hyperhidrosis treated with a unique targeted laser energy delivery method with 1-year follow up. J Drugs Dermatol 13:4 (2014): 449-456. 

Glaser DA, Galperin TA. Botulinum toxin for hyperhidrosis of areas other than the axillae and palms/soles. Dermatologic Clinics 32:4 (2014): 517-525.

Glaser DA. Oral medications. Dermatologic Clinics 32:4 (2014): 527-532.

Glaser DA, Galperin TA. Local procedural approaches for axillary hyperhidrosis. Dermatologic Clinics 32:4 (2014): 533-540. 

Glaser, DA, Galperin T. Managing hyperhidrosis: emerging therapies. Dermatologic Clinics 32:4 (2014): 549-553.

Gross KM, Schote AB, Schneider KK, Schulz A, Meyer J. Elevated social stress levels and depressive symptoms in primary hyperhidrosis. PLoS One. 2014;9(3):e92412. Published 2014 Mar 19. doi:10.1371/journal.pone.0092412

Hamm, Henning MD. Impact of hyperhidrosis on quality of life and its assessment. Dermatologic Clinics 32:4 (2014): 467-476.

Klar, Joakim, et al.  Abolished InsP3R2 function inhibits sweat secretion in both humans and mice. J Clin Invest doi:  10.1172/JCI70720.  Published online October 20, 2014. 

Kouris A, Armyra K, Christodoulou C, Karimali P, Karypidis D, Kontochristopoulos G. Quality of Life in Patients with Focal Hyperhidrosis before and after Treatment with Botulinum Toxin A. ISRN Dermatol. 2014;2014:308650. Published 2014 Feb 6. doi:10.1155/2014/308650

Laniosz V, Wetter DA, Godar DA. Dermatologic manifestations of fibromyalgia. Clin Rheumatol 2014 Jul;33(7):1009-13.

Lessa Lda R, Luz FB, De Rezende RM, et al. The psychiatric facet of hyperhidrosis: demographics, disability, quality of life, and associated psychopathology. J Psychiatr Pract. 2014;20(4):316-323. doi:10.1097/01.pra.0000452570.69578.31 (Abstract Only)

Mela S, Whitworth DE. The fist bump: a more hygienic alternative to the handshake.  American Journal of Infection Control 42:8 (2014):  916-917.

Moraites E et al. Endoscopic thoracic sympathectomy. Dermatologic Clinics 32:4 (2014): 541-548.

Moraites, Eleni MD, et al. Incidence and prevalence of hyperhidrosis. Dermatologic Clinics 32:4 (2014): 457-465.

Nestor MS, Park H. Safety and efficacy of micro-focused ultrasound plus visualization for the treatment of axillary hyperhidrosis. J ClinAesthet Dermatol 7:4 (2014):  14-21.

Pariser D,  Ballard A. Topical therapies in hyperhidrosis care. Dermatologic Clinics 32:4 (2014): 485-490.

Pariser D, Ballard A. Iontophoresis for palmar and plantar hyperhidrosis. Dermatologic Clinics 32:4 (2014): 491-494. 

Pariser DM. Incorporating diagnosis and treatment of hyperhidrosis into clinical practice. Dermatologic Clinics 32:4 (2014): 565-574.

Pieretti L. Resources for hyperhidrosis sufferers, patients, and health care providers. Dermatologic Clinics 32:4 (2014): 555-564. 

Pinson I  et al. Non-invasive short-wave guided radiofrequency device for long-term sweat reduction in patients with primary axillary hyperhidrosis:  a preliminary study, presented at the 34 ASLMS Annual Conference, April 4-6, 2014, Phoenix, AZ.

Shams K, Rzany B. Focal Hyperhidrosis. In: Williams HC, Bigby M, eds. Evidence-Based Dermatology, 3. John Wiley & Sons Ltd; 2014: 504-511.  doi:10.1002/9781118357606.ch59

Sklansky M et al. Banning the handshake from the health care setting. JAMA 311:24 (2014):  2477-2478.

Spenser, Samantha. From the Patient's Perspective: Traveling Far and Wide to Better Understand, Care For, and Cope with Hyperhidrosis. Journal of Dermatology for Physician Assistants. Vol. 8, No. 4, Fall 2014.

Trindade de Almeida A,  Montagner S. Botulinum toxin for axillary hyperhidrosis. Dermatologic Clinics 32:4 (2014): 495-504. 

Weinberg T et al. Botulinum neurotoxin treatment of palmar and plantar hyperhidrosis. Dermatologic Clinics 32:4 (2014): 505-515.

Wolosker N, Schvartsman C, Krutman M, et al. Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old. Pediatr Dermatol. 2014;31(1):48-53. doi:10.1111/pde.12142 (Abstract Only)

2013 studies

Augustin M, Radtke MA, Herberger K, Kornek T, Heigel H & Schaefer I. Prevalence and disease burden of hyperhidrosis in the adult population. Dermatology 227 (2013):  10-13. 

Biehle-Hulette S et al. Significant protection from event sweat – without a prescription, presented at the American Academy of Dermatology 71st Annual Meeting, March 1-5, 2013, Miami Beach, FL.

Coveliers H, Meyer M, Gharagozloo F, Wisselink W. Selective sympathectomy for hyperhidrosis: technique of robotic transthoracic selective postganglionic efferent sympathectomy. Eur J Cardiothorac Surg. 2013;43(2):428-430. doi:10.1093/ejcts/ezs411

Coveliers H, Meyer M, Gharagozloo F, et al. Robotic selective postganglionic thoracic sympathectomy for the treatment of hyperhidrosis. Ann Thorac Surg. 2013;95(1):269-274. doi:10.1016/j.athoracsur.2012.08.013

de Menezes LR. Visual scale for the quantification of hyperhidrosis. J. bras. Pneumol 39:4 (2013). 

El Kahky HM, Diab HM, Aly DG, Farag NM. Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar Hyperhidrosis. Dermatol Res Pract. 2013;2013:686329. doi:10.1155/2013/686329

Fatemi A. Apparatus for the treatment of hyperhidrosis. Patent EP 2645954 A1.  9 October 2013.

Fujimoto T, Kawahara K, Yokozeki H. Epidemiological study and considerations of primary focal hyperhidrosis in Japan:  fromquestionnaire analysis. J Dermatol 40:11 (2013):  886-890. 

Gong TK, Kim DW. Effectiveness of oral glycopyrrolate use in compensatory hyperhidrosis patients. Korean J Pain. 2013;26(1):89-93. doi:10.3344/kjp.2013.26.1.89

Gordon JRS, Hill SE. Update on pediatric hyperhidrosis. Dermatologic Therapy 26 (2013): 452-461.

Ibrahim O, Kakar R, Bolotin D, et al. The comparative effectiveness of suction-curettage and onabotulinumtoxin-A injections for the treatment of primary focal axillary hyperhidrosis: a randomized control trial. J Am Acad Dermatol. 2013;69(1):88-95. doi:10.1016/j.jaad.2013.02.013 (Abstract Only)

Jacob C. Treatment of hyperhidrosis with microwave technology. Seminars in Cutaneous Medicine and Surgery 32 (2013):  2-8.

Kuijpers M, Klinkenberg TJ, Bouma W, DeJongste MJ, Mariani MA. Single-port one-stage bilateral thoracoscopic sympathicotomy for severe hyperhidrosis: prospective analysis of a standardized approach. J Cardiothorac Surg. 2013;8:216. Published 2013 Nov 26. doi:10.1186/1749-8090-8-216

Lee S et al. The efficacy of a microwave device for treating axillary hyperhidrosis and osmidrosis in Asians: a preliminary study. J Cosmet Laser Ther 15:5 (2013):  255-259.

Patakfalvi L, Benohanian A. Treatment of palmar hyperhidrosis with needle-free injection of botulinum toxin A.  Arch Dermatol Res doi:  10.1007/s00403-013-1425-7

Rokhsar C, Kim MJ. A retrospective analysis of the treatment of axillary hyperhidrosis with a novel microwave technology, presented at the 33rd ASLMS Annual Conference, April 3-7, 2013, Boston, MA.

Scarff JR. Options for treating antidepressant-induced sweating. Current Psychiatry 12:1 (2013): 51.

Stefaniak TJ, Ćwigoń M. Long-term results of thoracic sympathectomy for primary hyperhidrosis. Pol Przegl Chir. 2013 May;85(5):247-52. doi: 10.2478/pjs-2013-0038. (Abstract Only) 

Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, et al. Genital powder use and risk of ovarian cancer: A pooled analysis of 8,525 cases and 9,859 controls. Cancer Prev Res (Phila). 2013 Aug;6(80): 811-21.

Wolosker N, Krutman M, Teivelis MP, et al. Quality of life before hyperhidrosis treatment as a predictive factor for oxybutynin treatment outcomes in palmar and axillary hyperhidrosis. Ann Vasc Surg. 2014;28(4):970-976. doi:10.1016/j.avsg.2013.07.032 (Abstract Only)

2012 studies

Bechara FG, et al. Effects of a long-pulsed 800-nm diode laser on axillary hyperhidrosis: a randomized controlled half-side comparison study. Dermatol Surg 38:5 (2012): 736-740. 

Gagnon L. Laser therapy provides permanent solution to hyperhidrosis. Dermatology Times, 1 July 2012.  

Glaser DA et al. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. Dermatol Surg 38 (2012): 185-191. 

Hong H et al. Clinical evaluation of a microwave device for treating axillary hyperhidrosis. Dermatol Surg doi: 10.1111/j.1524-4725.2012.02375.x. 

Johnson J et al.  Microwave thermolysis of sweat glands.  Lasers in Surgery and Medicine 44:1 (2012):  20-25. 

Kayser SC et al. Perioral gustatory sweating: case report. The Journal of Laryngology & Otology 126 (2012): 532-534.

Kern KU, Kohl M, Seifert U, Schlereth T. Effect of botulinum toxin type B on residual limb sweating and pain. Is there a chance for indirect phantom pain reduction by improved prosthesis use? Schmerz. 2012;26(2):176-184. doi:10.1007/s00482-011-1140-2 (Abstract Only)

Kerscher M et al. "Comparison of the spread of three botulinum toxin type A preparations". Arch Dermatol Res 304 (2012): 155-161.

Letada, PR, et al. Treatment of focal axillary hyperhidrosis using a long-pulsed Nd:YAG 1064 nm laser at hair reduction settings. J Drugs Dermatol 11:1 (2012): 59-63. 

Paller AS et al. Oral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis. J Am Acad Dermatol 67:5 (2012): 918-923.

Rubin D et al. “Second-hand stress: inhalation of stress sweat enhances neural response to neutral faces”. Soc Cogn Affect Neurosci 7:2 (2012): 208-212.

Salvaggio HL, Wagner A. Suture boots: an aid for the injection of onabotulinum toxin A for primary focal hyperhidrosis. Pediatric Dermatology doi: 10.1111/j.1525-1470.2012.01849.x. 

Swaile DF et al. Clinical studies of sweat rate reduction by an over-the-counter soft-solid antiperspirant and comparison with a prescription antiperspirant product in male panelists. Br J Dermatol 166 Suppl. 1 (2012): 22-26.

Wolosker N et al. "A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis". Journal of Vascular Surgery 55:6 (2012): 1696-1700.

Wolosker N et al. Evaluation of quality of life over time among 453 patients with hyperhidrosis submitted to endoscopic thoracic sympathectomy. Journal of Vascular Surgery 55:1 (2012): 154-156.

Walling H. Systemic therapy for primary hyperhidrosis: a retrospective study of 59 patients treated with glycopyrrolate or clonidine. J Am Acad Dermatol 66:3 (2012): 387-392.

2011 studies

Atkinson J  et al. Endoscopic transthoracic limited sympathotomy for palmar-plantar hyperhidrosis: outcomes and complications during a 10-year period. Mayo Clin Proc 86:8 (2011): 721-729.

Coveliers H, Atif S, Rauwerda J, Wisselink W. Endoscopic thoracic sympathectomy: long-term results for treatment of upper limb hyperhidrosis and facial blushing. Acta Chir Belg. 2011 Sep-Oct;111(5):293-7. (Abstract Only) 

Doft MA, et al. Treatment of axillary hyperhidrosis with botulinum toxin: a single surgeon's experience with 53 consecutive patients. Aesthetic Plast Surg 2011 May 11. 

Kern U, Kohl M, Seifert U, Schlereth T. Botulinum toxin type B in the treatment of residual limb hyperhidrosis for lower limb amputees: a pilot study. Am J Phys Med Rehabil. 2011;90(4):321-329. doi:10.1097/PHM.0b013e31820636fd (Abstract Only)

Kilmer S et al. A randomized, blinded clinical study of a microwave device for treatment of axillary hyperhidrosis, presented at the 31st ASLMS Annual Conference, April 1-3, 2011, Grapevine, TX.

Kotlus BS. Treatment of refractory axillary hyperhidrosis with a 1320-nm Nd:YAG laser. J Cosmet Laser Ther 13:4 (2011): 193-195. 

Lupin M et al. A multi-center evaluation of the miradry system to treat subjects with axillary hyperhidrosis, presented at the 31st ASLMS Annual Conference, April 1-3, 2011, Grapevine, TX.

Maletic D et al. Laser assisted reduction of axillary hyperhidrosis (LARAH) – evaluation of success up to 24 months after the treatment. J. LAHA 2011:1 (2011): 37-42. 

Martin A et al. Effective prevention of stress-induced sweating and axillary malodour formation in teenagers. J Cosmet Sci 33:1 (2011): 90-97.

Milanez de Campos JR et al. Is age group a predictive factor for satisfaction among patients undergoing sympathectomy to treat hyperhidrosis? J Vasc Bras 10:4 (2011): 284-288.

Saenz JW, Sams RW, Jamieson B. Treatment of Hyperhidrosis. Am Fam Physician. 2011 Feb 15;83(4):464-466.

Smidfelt K, Drott C. Late results of endoscopic thoracic sympathectomy for hyperhidrosis and facial blushing. Br J Surg. 2011 Dec;98(12):1719-24. doi: 10.1002/bjs.7682. Epub 2011 Sep 16. (Abstract Only) 

Smith SR. Evolution of a new treatment modality for primary focal hyperhidrosis, presented at Cosmetic Boot Camp 2011, June 14-17, 2011, Aspen, CO.

Vazquez LD, Staples NL, Sears SF, Klodell CT. Psychosocial functioning of patients after endoscopic thoracic sympathectomy. Eur J Cardiothorac Surg. 2011;39(6):1018-1021. doi:10.1016/j.ejcts.2011.01.059

Vergilis-Kalner IJ. Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature. J Drugs Dermatol. 2011;10(9):1013-1015. (Abstract Only)

Walling HW. Clinical differentiation of primary from secondary hyperhidrosis. J Am Acad Dermatol. 2011;64(4):690-695. doi:10.1016/j.jaad.2010.03.013 (Abstract Only)

Walling HW, Swick, BL. Treatment options for hyperhidrosis. Am J Clin Dermatol 12:5 (2011): 285-295.

Wang F et al. Comparison of compensatory sweating and quality of life following thoracic sympathetic block for palmar hyperhidrosis: electrocautery hook versus titanium clip. Chinese Medical Journal 124:21 (2011): 3495-3498.

Wolosker N et al. The use of oxybutynin for treating axillary hyperhidrosis. Annals of Vascular Surgery 25:8 (2011): 1057-1062.

Wolosker N et al. The use of oxybutynin for treating facial hyperhidrosis. An Bras Dermatol 86:3 (2011): 451-456.

Woolery-Lloyd H, Valins W. Aluminum chloride hexahydrate in a salicylic acid gel base: a case series of combination therapy with botulinum toxin type A for moderate to severe hyperhidrosis. Cutis 88:1 (2011): 43-45.

2010 studies

Aydin F, Pancar GS, Senturk N, et al. Axillary hair removal with 1064-nm Nd:YAG laser increases sweat production. Clin Exp Dermatol. 2010;35(6):588-592. doi:10.1111/j.1365-2230.2009.03638.x (Abstract Only)

Bellet JS. Diagnosis and treatment of primary focal hyperhidrosis in children and adolescents. Semin Cutan Med Surg 29:2 (2010): 121-126.

Cantarella G et al. Treatment of Frey’s syndrome with botulinum toxin B. Otolaryngol Head Neck Surg 143 (2010): 214-218.

Dressler D. Comparing Botox® and Xeomin® for axillar hyperhidrosis. J Neural Transm 117 (2010): 317-319.

Glaser DA et al. A randomized, blinded clinical evaluation of a novel microwave device for treatment of axillary hyperhidrosis, presented at the 2010 ASDS/ASCDAS Joint Annual Meeting, October 21-24, 2010, Chicago, IL.

Hill S. Hyperhidrosis Diagnosis and Management. Pediatric Rounds, a newsletter from the physicians of Children's Specialty Group, (Fall 2010) 12-14.

Kaminer MS et al.  First clinical use of a novel microwave device for treatment of axillary hyperhidrosis, presented at the American Society for Dermatologic Surgery 2010 Annual Meeting, October 21-24, 2010, Chicago, IL. 

Marques AH et al. Evaluation of stress symptoms by applying noninvasive methodologies: measurements of neuroimmune biomarkers in the sweat, heart rate variability and salivary cortisol. Neuroimmunomodulation 17:3 (2010): 205-208.

Milanez de Campos JR et al. Comparison of pain severity following video-assisted thoracoscopic sympathectomy: electric versus harmonic scalpels. Interactive Cardiovascular and Thoracic Surgery 10 (2010): 919-922.

Prasad A et al. Endoscopic thoracic sympathectomy for primary palmar hyperhidrosis. Surg Endosc 24 (2010): 1952-1957.

Shams K, Kavanagh GM. Immediate reduction in sweat secretion with electric current application in primary palmar hyperhidrosis. Archdermatol doi: 10.1001/archdermatol.2010.300.

Wait SD. et al. Thoracoscopic sympathectomy for hyperhidrosis:  analysis of 642 procedures with special attention to horner’s syndrome and compensatory hyperhidrosis.  Neurosurgery 67:3 (2010):  652-657.

Wolosker Nelson, et al. Is gender a predictive factor for satisfaction among patients undergoing sympathectomy to treat palmar hyperhidrosis? Clinics 65:6 (2010): 583-586.

Wolosker N et al. Quality of life before surgery is a predictive factor for satisfaction among patients undergoing sympathectomy to treat hyperhidrosis. Journal of Vascular Surgery 51:5 (2010): 1190-1194.

2009 studies

American Academy of Dermatology Responds to FDA Decision Regarding Botulinum Toxin Products, Schaumburg, IL, April 2009.

Baron JA, Zloty DM. Bilateral type 1 complex regional pain syndrome after local nerve blocks for palmar hyperhidrosis. Dermatol Surg 35 (2009): 885-887.

Carriere, I et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population. Arch Intern Med 169:14 (2009): 1317-1324.

Chow A, Wilder-Smith EP. Effect of transdermal botulinum toxin on sweat secretion in subjects with idiopathic palmar hyperhidrosis. Br J Dermatol 160:3 (2009): 721-722.

Commons, GW, Lim AF. Treatment of axillary hyperhidrosis/bromidrosis using Vaser ultrasound. Aesthetic Plast Surg 33:3 (2009): 312-323

Cruz J et al. Effects of endoscopic thoracic sympathectomy for primary hyperhidrosis on cardiac autonomic nervous activity. The Journal of Thoracic and Cardiovascular Surgery 137:3 (2009): 664-669.

de Bree R et al. Repeated botulinum toxin type A injections to treat patients with Frey syndrome. Arch Otolaryngol Head Neck Surg 135:3 (2009): 287-290.

Fibla JJ, Molins L, Mier JM, Vidal G. Effectiveness of sympathetic block by clipping in the treatment of hyperhidrosis and facial blushing. Interact Cardiovasc Thorac Surg. 2009;9(6):970-972. doi:10.1510/icvts.2009.212365

Flanagan KH, Glaser DA. An open-label trial of the efficacy of 15% aluminum chloride in 2% salicylic acid gel base in the treatment of moderate-to-severe primary axillary hyperhidrosis. Journal of Drugs in Dermatology 8:5 (2009): 477-480.

Goldman A, Wollina U. Subdermal Nd-YAG laser for axillary hyperhidrosis. Dermatol Surg 35:6 (June 2009):1018 

Grunfeld A et al. Botulinum toxin for hyperhidrosis. Am J Clin Dermatol 10:2 (2009): 87-102.

Jones T et al. Safety and tolerability of topical botulinum toxin type A in healthy adults, presented at the 69th Annual Meeting of the Society for Investigative Dermatology, May 2009, Montreal, Canada.

Keller SM et al. Diagnosis of palmar hyperhidrosis via questionnaire without physical examination. Clin Auton Res doi: 10.1007/s10286-009-0006-5. 

Kenny K. Diagnosis and treatment of hyperhidrosis. Nurse Practitioner: July 2009, Volume 34, Issue 7, p 10–11.

Kim WO et al. Botulinum toxin:  a treatment for compensatory hyperhidrosis in the trunk.  Dermatol Surg 35:5 (2009):  833-838.  

Mahendiran S et al. Hyperhidrosis: a review of a medical condition. The Open Dermatology Journal 3 (2009): 195-197.

Martins Rua JF, Jatene FB, de Campos JR, et al. Robotic versus human camera holding in video-assisted thoracic sympathectomy: a single blind randomized trial of efficacy and safety. Interact Cardiovasc Thorac Surg. 2009;8(2):195-199. doi:10.1510/icvts.2008.191353

Miller DL et al. Effect of sympathectomy level on the incidence of compensatory hyperhidrosis after sympathectomy for palmar hyperhidrosis. J Thorac Cardiovasc Surg 138 (2009): 581-585.

Mujica-Parodi LR et al. Chemosensory cues to conspecific emotional stress activate amygdale in humans. PLoS One doi: 10.1371/journal.pone.0006415. 

Ng S et al. Management of Frey syndrome using botulinum neurotoxin: a case report. JCDA 75:9 (2009): 651-654.

Prehn-Kristensen A et al. Induction of empathy by the smell of anxiety. PLoS One doi: 10.1371/journal.pone.0005987. 

Scully C et al. Marathon of eponyms: 6 Frey syndrome (gustatory sweating). Oral Diseases 15 (2009): 608-609.

Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patients. J Am Acad Dermatol doi: 10.1016/j.jaad.2009.02.038.

2008 studies

Bahmer FA, Sachse MM. Hyperhidrosis area and severity index. Dermatol Surg 34 (2008): 1744-1745.

Cetindag IB, Boley TM, Webb KN, Hazelrigg SR. Long-term results and quality-of-life measures in the management of hyperhidrosis. ThoracSurg Clin 18:2 (2008):  217-222. 

Cheshire WP, Fealey RD. Drug-induced hyperhidrosis and hypohidrosis. Drug Safety 31:2 (2008): 109-126.

Cliff SH, Judodihardjo H, Eltringham E. Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. J Cosmet Dermatol. 2008;7(1):50-54. doi:10.1111/j.1473-2165.2008.00361.x (Abstract Only)

Efthymiou CA, Thorpe JAC. Compensatory hyperhidrosis: a consequence of truncal sympathectomy treated by video assisted application of botulinum toxin and reoperation. European Journal of Cardio-thoracic Surgery 33 (2008): 1157-1158.

Flanagan KH et al. Botulinum toxin type A versus topical 20% aluminum chloride for the treatment of moderate to severe primary focal axillary hyperhidrosis. Journal of Drugs in Dermatology 7:3 (2008): 221-227.

Gelbard CM et al. Primary pediatric hyperhidrosis: a review of current treatment options. Pediatric Dermatology 25:6 (2008): 591-598.

Hartl DM, et al. Botulinum toxin A for quality of life improvement in post-parotidectomy gustatory sweating (Frey’s syndrome). The Journal of Laryngology & Otology 122 (2008): 1100-1104.

Honeyman JF et al. Efficacy of botulinum toxin for a congenital eccrine naevus. J Eur Acad Dermatol Venereol 22:10 (2008): 1275-1276.

Kim WO et al. Topical glycopyrrolate for patients with facial hyperhidrosis. Br J Dermatol 158 (2008): 1094-1097.

Kossintseva I, Barankin B. Improvement in both raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment. Journal of Cutaneous Medicine and Surgery 12:4 (2008): 189-193.

Laing TA et al. Botulinum toxin for treatment of glandular hypersecretory disorders. Journal of Plastic, Reconstructive & Aesthetic Surgery 61 (2008): 1024-1028.

Munia MAS et al. Sustained benefit lasting one year from T4 instead of T3-T4 sympathectomy for isolated axillary hyperhidrosis. Clinics 63:6 (2008): 771-774.

Smalls LK et al. Clinical comparison of otc products labeled prescription strength wetness protection to prescription antiperspirants, presented at the 66th Annual Meeting of the American Academy of Dermatology, February 1-5, 2008, San Antonio, TX.

Smalls LK et. al. Chromophore mapping of hemoglobin for the assessment of axillary irritation: comparison of otc and prescription antiperspirants, presented at the 66th Annual Meeting of the American Academy of Dermatology, February 1-5, 2008, San Antonio, TX.

Walles T, Somuncuoglu G, Steger V, Veit S, Friedel G. Long-term efficiency of endoscopic thoracic sympathicotomy: survey 10 years after surgery. Interact Cardiovasc Thorac Surg. 2009 Jan;8(1):54-7. doi: 10.1510/icvts.2008.185314. Epub 2008 Sep 30. (Abstract Only) 

2007 studies

Aghaei S. Botulinum toxin therapy for palmar hyperhidrosis: experience in an Iranian population. The International Society of Dermatology 46 (2007): 212-214.

Bechara FG et al. Focal hyperhidrosis of the anal fold: successful treatment with botulinum toxin A. Dermatol Surg 33 (2007): 924-927.

Chang YT, Li HP, Lee JY, Lin PJ, Lin CC, Kao EL, Chou SH, Huang MF. Treatment of palmar hyperhidrosis: T(4) level compared with T(3) and T(2). Ann Surg. 2007 Aug;246(2):330-6. (Abstract Only) 

Charrow A, DiFazio M, Foster L, Pasquina PF, Tsao JW. Intradermal botulinum toxin type A injection effectively reduces residual limb hyperhidrosis in amputees: a case series. Arch Phys Med Rehabil. 2008;89(7):1407-1409. doi:10.1016/j.apmr.2007.11.054 (Abstract Only)

de Bree R et al. Management of Frey syndrome. Head & Neck 29:8 (2007): 773-778.

Glaser DA et al. Primary focal hyperhidrosis: scope of the problem. Cutis 79:suppl 5 (2007): 5-17.

Glaser DA et al. Palmar and plantar hyperhidrosis: best practice recommendations and special considerations. Cutis 79:suppl 5 (2007): 18-28.

Glaser DA et al. Facial hyperhidrosis: best practice recommendations and special considerations. Cutis 79:suppl 5 (2007): 29-32.

Glaser DA et al. Functional and dermatology-specific quality of life benefits with repeated botulinum toxin type A treatment of primary axillary hyperhidrosis over 4 years, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.

Glaser DA et al. 4-Year longitudinal data on the efficacy and safety of repeated botulinum toxin type A therapy for primary axillary hyperhidrosis, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.

Glogau RG. Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. Dermatol Surg 33 (2007): S76-S80.

Kessler E et al. A demographical study of hyperhidrosis, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.

Lear W et al. An epidemiological study of hyperhidrosis. Dermatol Surg 33 (2007): S69-S75.

Malmivaara A, Kuukasjärvi P, Autti-Ramo I, Kovanen N, Mäkelä M. Effectiveness and safety of endoscopic thoracic sympathectomy for excessive sweating and facial blushing: a systematic review. Int J Technol Assess Health Care. 2007 Winter;23(1):54-62. Review. (Abstract Only) 

Munia MAS et al. A randomized trial of T3-T4 versus T4 sympathectomy for isolated axillary hyperhidrosis. Journal of Vascular Surgery 45:1 (2007): 130-133.

Na GY et al. Control of palmar hyperhidrosis with a new 'dry-type' iontophoretic device. Dermatol Surg 33 (2007): 57-61.

NAD Examines Advertising for P&G's Secret Clinical Strength, NAD News, National Advertising Review Council, New York, NY, July 2007.

Naumann M, Hamm H, Kinkelin I, Reineis K.  Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions.  European Journal of Neurology.  2007; https://doi.org/10.1111/j.1468-1331.1999.tb00027.x.(Abstract Only)

Pomprasit M, Chintrakam C. Treatment of Frey’s syndrome with botulinum toxin. J Med Assoc Thai 90:11 (2007): 2397-2402.

Ram R et al. Current and emerging therapeutic modalities for hyperhidrosis, part 2: moderately invasive and invasive procedures. Cosmetic Dermatology 79 (2007): 281-288.

Solish N et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the canadian hyperhidrosis advisory committee. Dermatol Surg 33 (2007): 908-923.

Talarico-Filho S et al. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg 33 (2007): S44-S50.

Thomas M et al. Alternative topical treatment to an aluminum chloride antiperspirant that provides prescription strength efficacy with significantly less irritation, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.

2006 studies

Bakke M et al. Treatment of gustatory sweating with low-dose botulinum toxin A. Acta Odontologica Scandinavica 64:3 (2006): 129-133.

Barankin B et al. Treatment of inguinal hyperhidrosis with botulinum toxin type A. International Journal of Dermatology 45 (2006): 985-986.

Dressler D, Eleopra R. Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotoxicity Research 9:2-3 (2006): 121-125.

Glaser DA. The use of botulinum toxins to treat hyperhidrosis and gustatory sweating syndrome. Neurotoxicity Research 9:2-3 (2006): 173-178.

Hamm H et al. Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology 2006 212 (2006): 343-353.

Izadi S et al. Mydriasis and accommodative failure from exposure to topical glycopyrrolate used in hyperhidrosis.  J Neuroophthalmol 26 (2006):  232-233.  

Kavanagh GM, Shams K. Botulinum toxin type A by iontophoresis for primary palmar hyperhidrosis. Journal of the American Academy of Dermatology 55:5 (2006): S115-S117.

Kavanagh GM et al. Topical glycopyrrolate should not be overlooked in treatment of focal hyperhidrosis. British Journal of Dermatology 155:2 (2006): 487.

Khoo SG et al. The use of botulinum toxin in Frey’s syndrome. IMJ 99:5 (2006): 136-137.

Lim ECH et al. Topical botulinum toxin to treat hyperhidrosis? No sweat! Medical Hypotheses 67 (2006): 27-32.

Milanez de Campos JR et al. Axillary hyperhidrosis: T3/T4 versus T4 thoracic sympathectomy in a series of 276 cases. Journal of Laparoendoscopic & Advanced Surgical Techniques 16:6 (2006): 598-603.

Moya J et al. Thoracic sympathicolysis for primary hyperhidrosis. Surg Endosc 20 (2006): 598-602.

Pariser D et al. Effect of botulinum toxin type A treatment for severe primary axillary hyperhidrosis on work performance and productivity: results from an open-label clinical study, presented at the 64th Annual Meeting of the American Academy of Dermatology, March 3-7, 2006, San Francisco, CA.

Thomas M et al. Panel discussions among hyperhidrosis patients to assess lifestyle limitations, treatment regimes, and compensating behaviors, presented at the 64th Annual Meeting of the American Academy of Dermatology, March 3-7, 2006, San Francisco, CA.

2005 studies

Boboschko I, Jockenhöfer S, Sinkgraven R, Rzany B. Hyperhidrose als Risikofaktor der Tinea pedis [Hyperhidrosis as risk factor for tinea pedis]. Hautarzt. 2005;56(2):151-155. doi:10.1007/s00105-004-0849-6 (Abstract Only)

Cliff SH, Reeken S. Axillary hyperhidrosis and botox responding to demands: starting a nurse-led service. Nurse2Nurse 5:1 (2005): 28-30.

Eisenach JH et al. Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clinic Proceedings 80:5 (2005): 657-666.

Glaser DA et al. Effect of repeated botulinum toxin type A treatment on health related quality of life and functioning in patients with primary axillary hyperhidrosis: results from 2 years of longitudinal data, presented at ACADEMY '05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.

Glaser DA et al. Efficacy and safety of repeated botulinum toxin type A treatment for primary axillary hyperhidrosis: 12-month interim analysis of a multicenter, open-label trial, presented at ACADEMY ’05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.

Haider A, Solish N.Focal hyperhidrosis: diagnosis and management. CMAJ 172:1 (2005): 1-7.

Kowalski JW et al. Cost-effectiveness and budget impact of botulinum toxin type A (BoNTA) treatment for severe primary axillary hyperhidrosis inadequately managed with topical agents, presented at ACADEMY ’05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.

Krogstad AL et al. No compensatory sweating after botulinum toxin treatment of palmar hyperhidrosis. Br J Dermatol 152:2 (Feb 2005): 329-333.

Neumayer C et al. Effect of endoscopic thoracic sympathetic block on plantar hyperhidrosis. Arch Surg 140: 676-680 (2005).

Ogata A, et al. Low and high frequency acupuncture stimulation inhibits mental stress-induced sweating in humans via different mechanisms. Auton Neurosci 118: 1-2 (2005): 93-101.

Solish N et al. Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of life. Dermatol Surg 31:4 (2005): 405-413.

Swaile D, Chabi G, Putnam C. Clinical comparison of antiperspirant efficacy as a function of morning and/or nighttime application, presented at ACADEMY '05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.

Weber A et al. Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A. British Journal of Dermatology, (2005) 152: 342–345.

2004 studies

Campanati A et al. Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements. Journal of the American Academy of Dermatology 51:3 (2004): 345-348.

Carruthers A, Carruthers J. Long-term safety review of subjects treated with botulinum toxin type A for cosmetic use, presented at the American Academy of Dermatology Summer Meeting, July 28- August 1, 2004, New York, NY.

Dickerson SS, Kemeny ME. Acute stressors and cortisol responses: a theoretical integration and synthesis of laboratory research. Psychol Bull 130:3 (2004): 355-391.

Dolianitis C et al. Iontophoresis with glycopyrrolate for the treatment of palmoplantar hyperhidrosis. Australasian Journal of Dermatology 45 (2004): 208-212.

Glaser DA et al. Botulinum toxin type A improves occupational impairment associated with primary axillary hyperhidrosis and results in high levels of satisfaction with treatment, presented at the American Academy of Dermatology Summer Meeting, July 28- August 1, 2004, New York, NY.

Hexsel DM et al. Inguinal, or hexsel’s hyperhidrosis. Clinics in Dermatology 22 (2004): 53-59.

Hornberger J et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. Journal of the American Academy of Dermatology 51:2 (2004): 274-286.

Hund M et al. Randomised, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methanthelinium bromide (Vagantin®) in the treatment of focal hyperhidrosis. JDDG;2004· 2:343-349. (English, without graphs)

Hund M et al. Randomised, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methanthelinium bromide (Vagantin®) in the treatment of focal hyperhidrosis. JDDG;2004· 2:343-349. (German, with graphs)

Kavanagh GM et al. Botox® delivery by iontophoresis. British Journal of Dermatology 151 (2004): 1093-1095.

Kowalski JW, Eadie N, Dagget S, Lai PY. Validity and reliability of the hyperhidrosis disease severity scale (HDSS). J Am Acad Dermatol 50:3 (2004):  P51.

Lee J et al. A case of foul genital odor treated with botulinum toxin A. Dermatologic Surgery doi: 10.1111/j.1524-4725.2004.30382.x. 

Lowe N et al. The place of botulinum toxin type A in the treatment of focal hyperhidrosis. Br J Dermatol 151:6 (Dec 2004): 1115-1122.

Naumann M, Jost W.  Botulinum toxin treatment of secretory disorders.  Movement Disorders.  2004; https://doi.org/10.1002/mds.20067. (Abstract Only)

Ojimba TA, Cameron AEP. Drawbacks of endoscopic thoracic sympathectomy. British Journal of Surgery 91 (2004): 264-269.

Strutton D et al. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. Journal of the American Academy of Dermatology 51:2 (2004): 241-248.

Thomas S, Brown J, Vafaie J, Schwartz R. Palmoplantar Hyperhidrosis: A Therapeutic Challenge. Am Fam Physician. 2004 Mar 1;69(5):1117-1121.

2003 studies

Atkinson JLD, Fealey RD. Sympathotomy instead of sympathectomy for palmar hyperhidrosis: minimizing postoperative compensatory hyperhidrosis. Mayo Clinic Proceedings 78:2 (2003): 167-172.

Baumann L. Systemic adverse effects after botulinum toxin type B (myobloc) injections for the treatment of palmar hyperhidrosis. Arch Dermatol 139 (2003): 226-227.

Belin E, Polo J. Treatment of compensatory hyperhidrosis with botulinum toxin type A. Cutis 71 (2003): 68-70.

Blaheta H, Deusch H, Rassner G, Vollert B. Intravenous regional anesthesia (Bier's block) is superior to a peripheral nerve block for painless treatment of plantar hyperhidrosis with botulinum toxin. J Am Acad Dermatol 48:2 (2003): 302-304.

Cameron AE. Specific complications and mortality of endoscopic thoracic sympathectomy. Clin Auton Res. 2003 Dec;13 Suppl 1:I31-5.  (Abstract Only) 

Connolly M, de Berker D. Management of primary hyperhidrosis. Am J Clin Dermatol 4:10 (2003): 681-697.

de Campos JR, Kauffman P, Werebe Ede C, et al. Quality of life, before and after thoracic sympathectomy: report on 378 operated patients. Ann Thorac Surg. 2003;76(3):886-891. doi:10.1016/s0003-4975(03)00895-6 (Abstract Only)

Goodman, G. Diffusion and short-term efficacy of botulinum toxin A after the addition of hyaluronidase and its possible application for the treatment of axillary hyperhidrosis. Dermatol Surg 29:5 (2003): 533-538.

Gossot D et al. Long-term results of endoscopic thoracic sympathectomy for upper limb hyperhidrosis. Ann Thoracic Surg 75 (2003): 1075-1079.

Kaufmann H et al. Primary hyperhidrosis. Clin Auton Res 13 (2003): 96-98.

Lowe P, Cerdan-Sanz S, Lowe N. Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis: efficacy and duration with repeated treatments. Dermatol Surg 29 (2003): 545-548.

Matthews B et al. Thoracoscopic sympathectomy for palmaris hyperhidrosis. Southern Medical Journal 96:3 (2003): 254-258.

Naumann, M et al. Comparing the quality of life effect of primary focal hyperhidrosis to other dermatological conditions as assessed by the dermatology life quality index (DLQI). Value In HealthThe Journal of The International Society for Pharmacoeconomics and Outcomes Research 6:3 (2003): 242.

Naumann M et al. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months. Arch Dermatol 139 (2003): 731-736.

Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol. 2003;149(5):1041-1045. doi:10.1111/j.1365-2133.2003.05620.x

2002 studies

Ackerl K et al. The scent of fear. Neuro Endocrinol Lett 23:2 (2002): 79-84.

Altman R, Schwartz R. Emotionally induced hyperhidrosis. Cutis 69:5 (2002): 336-338.

Anliker M, Kreyden O.  Tap water iontophoresis.  Curr Probl Dermatol 30 (2002):  48-56.

Aoki K.  Physiology and pharmacology of therapeutic botulinum neurotoxins.  Curr Probl Dermatol 30 (2002):  107-116.

Atkins JL, Butler PE. Hyperhidrosis:  a review of current management. Plast Reconstr Surg 110 (2002):  222-228.  

Beerens A, Snow G. Botulinum toxin A in the treatment of patients with Frey syndrome. British Journal of Surgery 89 (2002): 116-119.

Boni R.  Generalized hyperhidrosis and its systemic treatment.  Curr Probl Dermatol 30 (2002):  44-47.

Chuang K, Liu J. Long-term assessment of percutaneous sterotactic thermocoagulation of upper thoracic ganglionectomy and sympathectomy for palmar and craniofacial hyperhidrosis in 1742 cases. Neurosurgery 51:4 (2002): 963-969.

Davidson JRT et al. Hyperhidrosis in social anxiety disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 26 (2002): 1327-1331.

Geiges M.  The history of botulism.  Curr Probl Dermatol 30 (2002):  77-93.

Groscurth P. Anatomy of sweat glands. Curr Probl Dermatol 30 (2002): 1-9.

Hafner J, Beer G.  Axillary sweat gland excision.  Curr Probl Dermatol 30 (2002):  57-63.

Heckmann M.  Hyperhidrosis of the axilla.  Curr Probl Dermatol 30 (2002):  149-155.

Holzle E.  Pathophysiology of sweating.  Curr Probl Dermatol 30 (2002):  10-22.

Holzle E.  Topical pharmacological treatment.  Curr Probl Dermatol 30 (2002):  30-43.

Huh C, Han K, Seo K, Eun H.  Botulinum toxin treatment for a compensatory hyperhidrosis subsequent to an upper thoracic sympathectomy.  Journal of Dermatological Treatment 13 (2002):  91-93.

Hund M, Kinkelin I, Naumann M, Hamm H.  Definition of axillary hyperhidrosis by gravimetric assessment.  Arch Dermatol 138 (2002):  539-541.

Karakoç Y, et al. Safe control of palmoplantar hyperhidrosis with direct electrical current. Int J Dermatol 41 (2002): 602-605.

Kestenholz P, Weder W.  Thoracic sympathectomy.  Curr Probl Dermatol 30 (2002):  64-76.

Kreyden O.  Botulinum toxin:  from poison to pharmaceutical.  Curr Probl Dermatol 30 (2002):  94-100. 

Kreyden O.  Rare forms of hyperhidrosis.  Curr Probl Dermatol 30 (2002):  178-187.

Laskawi R, Rohrbach S.  Frey's syndrome.  Treatment with botulinum toxin.  Curr Probl Dermatol 30 (2002):  170-177.

Lin T, Chou M. Needlescopic thoracic sympathetic block by clipping for craniofacial hyperhidrosis. Surg Endosc 16 (2002): 1055-1058.

Lowe N et al. Efficacy and safety of botulinum toxin type A in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg 28 (2002): 822-827.

Luh J, Blackwell T. Craniofacial hyperhidrosis successfully treated with topical glycopyrrolate. South Med J 95:7 (2002): 756-758.

Moraru E, Auff E, Schnider P.  Hyperhidrosis of the palms and soles.  Curr Probl Dermatol 30 (2002):  156-169.

Naumann M, Hamm H.  Treatment of axillary hyperhidrosis.  British Journal of Surgery 89 (2002):  259-261.

Naumann MK et al. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Brit J Dermatol 147 (2002): 1218-1226.

Odderson I.  Long-term quantitative benefits of botulinum toxin type A in the treatment of axillary hyperhidrosis.  Dermatol Surg 28 (2002):  480-483.

Proebstle T, Schneiders V, Knop J.  Gravimetrically controlled efficacy of subcorial curettage:  a prospective study for treatment of axillary hyperhidrosis.  Dermatol Surg 28 (2002):  1022-1026.

Restivo D et al.  Improvement of diabetic autonomic gustatory sweating by botulinum toxin type A.  Neurology 59 (2002):  1971-1973.

Ro KM, Cantor RM, Lange KL, Ahn SS. Palmar hyperhidrosis:  evidence of genetic transmission. J Vasc Surg 35:2 (2002):  382-386. 

Rossetto O, Seveso M, Caccin P, Montecucco C.  Botulinum neurotoxins are metalloproteases specific for SNARE proteins involved in neuroexocytosis.  Curr Probl Dermatol 30 (2002):  117-125.

Ruchinskas R, Narayan R, Meagher R, Furukawa S.  Psychodermatology:  the relationship of psychopathology and hyperhidrosis.  British Journal of Dermatology 147 (2002):  733-735.

Schaffner R, Kreyden O.  Complications and side-effects of botulinum toxin A.  Curr Probl Dermatol 30 (2002):  141-148.

Tan SR, Solish N. Long-term efficacy and quality of life in the treatment of focal hyperhidrosis with botulinum toxin A. Dermatol Surg 28:6 (2002): 495-499.

Tögel B et al. Current therapeutic strategies for hyperhidrosis: a review. Eur J Dermatol 12 (2002):  219-223. 

Wollina U, Karamfilov T.  Botulinum toxin A for palmar hyperhidrosis.  Journal of The European Academy of Dermatology and Venereology.  2002; https://doi.org/10.1046/j.1468-3083.2001.00350.x(Abstract Only)

Wollina U, Karamfilov T, Konrad H.  High-dose botulinum toxin type A therapy for axillary hyperhidrosis markedly prolongs the relapse-free interval.  J Am Acad Dermatol 46:4 (2002):  536-540.

2001 studies

Chen H, Lu K, Liang C. Transthoracic endoscopic T-2, 3 sympathectomy for facial hyperhidrosis. Autonomic Neuroscience: Basic and Clinical 93 (2001): 91-94.

Fujita M, Mann T, Mann O, Berg D. Surgical pearl: use of nerve blocks for botulinum toxin treatment of palmar-plantar hyperhidrosis. J Am Acad Dermatol 45 (2001): 587-589.

Glogau, R. Treatment of palmar hyperhidrosis with botulinum toxin. Seminars in Cutaneous Medicine and Surgery 20:2 (2001): 101-108.

Heckmann M, Ceballos-Baumann A, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 344:7 (2001): 488-493.

Heckmann M, Schaller M, Breit S, Plewig G. Evaluation of therapeutic success of hyperhidrosis therapy. Arch Dermatol 137 (2001): 94.

Hsu C, Shia S, Hsia J, Chuang C, Chen, C.  Experiences in thoracoscopic sympathectomy for axillary hyperhidrosis and osmidrosis.  Arch Surg 136 (2001):  1115-1117.

Kreyden O, Schmid-Grendelmeier P, Burg G.  Idiopathic localized unilateral hyperhidrosis.  Arch Dermatol 137 (2001):  1622-1625.

Naumann M.  Evidence-based medicine:  botulinum toxin in focal hyperhidrosis.  J Neurol 248 :S:Suppli (2001):  31-33. :S:Suppli (2001):  31-33.

Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomized, parallel group, double blind, placebo controlled trial. BMJ 323 (2001): 596-599.

Rompel R, Scholz S.  Subcutaneous curettage vs. injection of botulinum toxin A for treatment of axillary hyperhidrosis.  JEADV 15 (2001):  207-211.

Saadia D, Voustianiouk A, Wang A, Kaufmann H.  Botulinum toxin type A in primary palmar hyperhidrosis.  Neurology 57 (2001):  2095-2099.

Schnider P et al. Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow-up in 61 patients. British Journal of Dermatology 145 (2001): 289-293.

Swartling C, Naver H, Lindberg M.  Botulinum A toxin improves life quality in severe primary focal hyperhidrosis.  European Journal of Neurology 8 (2001):  247-252.

Swartling C, Farnstrand C, Abt G, Stalberg E, Naver H.  Side effects of intradermal injections of botulinum A toxin in the treatment of palmar hyperhidrosis:  a neurophysiological study.  European Journal of Neurology 8 (2001):  451-456.

Trindade de Almeida A, Kadunc B, Martins de Oliveira E. Improving botulinum toxin therapy for palmar hyperhidrosis: wrist block and technical considerations. Dermatol Surg 27:1 (2001): 34-36.

2000 studies

Amir M et al. Impairment in quality of life among patients seeking surgery for hyperhidrosis (excessive sweating): preliminary results. Isr J Psychiatry Relat Sci 37:1 (2000): 25-31.

Birner P et al. Cardiac autonomic function in patients suffering from primary focal hyperhidrosis. Eur Neurol 44 (2000): 112-116.

Böger A, Herath H, Rompel R, Ferbert A. Botulinum toxin for treatment of craniofacial hyperhidrosis. J Neurol. 2000;247(11):857-861. doi:10.1007/s004150070073 (Abstract Only)

Collin J, Whatling P. Treating hyperhidrosis: surgery and botulinum toxin are treatments of choice in severe cases. BMJ 320 (2000):  1221-1222.

Huang W, Foster J, Rogachefsky A.  Pharmacology of botulinum toxin.  J Am Acad Dermatol 43 (2000):  249-259.

Karamfilov T, Konrad H, Karte K, Wollina U.  Lower relapse rate of botulinum toxin A therapy for axillary hyperhidrosis by dose increase.  Arch Dermatol 136 (2000):  487-490.

Kinkelin I et al. Effective treatment of frontal hyperhidrosis with botulinum toxin A. British Journal of Dermatology143:4 (2000): 824-827.

Klein A, Glogau R.  Botulinum toxin:  beyond cosmesis.  Arch Dermatol 136 (2000):  539-541.

Manca D, Valls-Sole J, Callejas M. Excitability recovery curve of the sympathetic skin response in healthy volunteers and patients with palmar hyperhidrosis. Clinical Neurophysiology 111 (2000): 1767-1770.

Reisfeld R, Nguyen R, Pnini A. Endoscopic thoracic sympathectomy for treatment of essential hyperhidrosis syndrome: experience with 650 patients. Surg Laparosc Endosc Percutan Tech. 2000 Feb;10(1):5-10. (Abstract Only) 

Solomon B, Hayman R. Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol 42:6 (2000): 1026-1029.

Schnider P et al. High-dose botulinum toxin type A for axillary hyperhidrosis. Arch Dermatol 136 (2000): 1567.

Sung S, Kim Y, Kim J.  Ultra-thin needle thoracoscopic surgery for hyperhidrosis with excellent cosmetic effects.  European Journal of Cardio-thoracic Surgery 17 (2000):  691-696.

Swinehart JM. Treatment of axillary hyperhidrosis: combination of the starch-iodine test with the tumescent liposuction technique. Dermatol Surg 26 (2000): 392-396.

Yamamoto H, Kanehira A, Kawamura M, Okada M, Ohkita Y. Needlescopic surgery for palmar hyperhidrosis. The Journal of Thoracic and Cardiovascular Surgery 120:2 (2000): 276-279.

1999 studies

Cina CS, Clase CM. The illness intrusiveness rating scale: a measure of severity in individuals with hyperhidrosis. Qual Life Res 8 (1999):693-698.  

Heckmann M et al. Side-controlled intradermal injection of botulinum toxin A in recalcitrant axillary hyperhidrosis. J Am Acad Dermatol 41:6 (1999): 987-990.

Imhof M et al.  Long-term results of 45 thoracoscopic sympathicotomies for primary hyperhidrosis in children.  Journal of Pediatric Surgery 34:12 (1999):  1839-1842.

Laccourreye O et al.  Recurrent gustatory sweating (frey's syndrome) after intracutaneous injection of botulinum toxin type A.  Arch Otolaryngol Head Neck Surg 125 (1999):  283-286.

Laskawi R, Ellies M, Rodel R, Schoenebeck C. Gustatory sweating: clinical implications and etiologic aspects. J Oral Maxillofac Surg 57 (1999): 642-648.

Leung AK, Chan PY, Choi MC. Hyperhidrosis. Int J Dermatol 38:8 (1999):  561-567. 

Zacherl J et al.  Long-term results of 630 thoracoscopic sympathicotomies for primary hyperhidrosis:  the Vienna experience.  Eur J Surg 164:Suppl 580 (1998):  43-46.

1998 studies

Benohanian A et al. Localized hyperhidrosis treated with aluminum chloride in a salicylic acid gel base. International Journal of Dermatology 37 (1998): 701-703.

Glogau RG.  Botulinum A neurotoxin for axillary hyperhidrosis.  No sweat Botox. Dermatol Surg 24 (1998):  817-819. 

Heckmann M. Complications in patients with palmar hyperhidrosis treated with transthoracic endoscopic sympathectomy. Neurosurgery 42:6 (1998): 1403-1404.

Naumann M et al.  Focal hyperhidrosis.  Effective treatment with intracutaneous botulinum toxin.  Arch Dermatol 134 (1998):  301-304.

Rex L, Drott C, Claes G, Gothberg G, Dalman P.  The Boras experience of endoscopic thoracic sympathicotomy for palmar, axillary, facial hyperhidrosis and facial blushing.  Eur J Surg 164:Suppl 580 (1998):  23-26.

Stolman LP. MD. Treatment of hyperhidrosis. Dermatologic Clinics 16:4 (October 1998): 863-867.

Telaranta T.  Treatment of social phobia by endoscopic thoracic sympathicotomy.  Eur J Surg 164:Suppl 580 (1998):  27-32. 

Zacherl J et al.  Long-term results of 630 thoracoscopic sympathicotomies for primary hyperhidrosis:  the Vienna experience.  Eur J Surg 164:Suppl 580 (1998):  43-46.

1997 studies

Andrews B, Rennie J. Predicting changes in the distribution of sweating following thoracoscopic sympathectomy. British Journal of Surgery 84 (1997): 1702-1704.

Garber A. Benztropine in the Treatment of Venlafaxine-Induced Sweating. J Clin Psychiatry 58:4 (1997): 176-177.

Iwase S et al.  Altered response in cutaneous sympathetic outflow to mental and thermal stimuli in primary palmoplantar hyperhidrosis.  Journal of the Autonomic Nervous Systems 64 (1997):  65-73.

Lai Y, Yang L, Chio C, Chen H. Complications in patients with palmar hyperhidrosis treated with transthoracic endoscopic sympathectomy. Neurosurgery 41:1 (1997): 110-113.

Naumann M et al.  Botulinum toxin for palmar hyperhidrosis.  The Lancet 349 (1997):  252.

Noppen M, Sevens C, Gerlo E, Vincken W.  Plasma catecholamine concentrations in essential hyperhidrosis and effects of thoracoscopic D2-D3 sympathicolysis.  European Journal of Clinical Investigation 27 (1997):  202-205.

Park JH et al. Carbon dioxide laser treatment vs subcutaneous resection of axillary osmidrosis. Dermatol Surg 23:4 (1997): 247-251.

Parslew R, Lewis-Jones M.  Localized unilateral hyperhidrosis secondary to an eccrine naevus.  Clinical and Experimental Dermatology 22 (1997):  246-247

Sampaio C, Ferreira JJ, Simões F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1. Mov Disord. 1997;12(6):1013-1018. doi:10.1002/mds.870120627 (Abstract Only)

Schnider P et al. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. British Journal of Dermatology 136 (1997): 548-552.

Shaw J et al. A randomised controlled trial of topical glycopyrrolate, the first specific treatment for diabetic gustatory sweating. Diabetologia 40 (1997): 299-301.

1996 studies

Kao M, Chen Y, Lin J, Hsieh C, Tsai J.  Endoscopic sympathecomy treatment for craniofacial hyperhidrosis.  Arch Surg 131 (1996):  1091-1094.

1995 studies

Drott C, Gothberg G, Claes G. Endoscopic transthoracic sympathectomy: an efficient and safe method for the treatment of hyperhidrosis. Journal of the American Academy of Dermatology 33:1 (1995): 78-81.

Feder R. Clonidine treatment of excessive sweating. J Clin Psychiatry 56:1 (1995): 35.

Orteu C, McGregor J, Almeyda J, Rustin M.  Recurrence of hyperhidrosis after endoscopic transthoracic sympathectomy—case report and review of the literature.  Clinical and Experimental Dermatology 20 (1995):  230-233.

1994 studies

Bushara K, Park D. Botulinum toxin and sweating. Journal of Neurology, Neurosurgery and Psychiatry 57:11 (1994): 1437-1438.

Canaday B, Stanford R. Propantheline bromide in the management of hyperhidrosis associated with spinal cord injury. The Annals of Pharmacotherapy 29 (1995): 489-492.

Herbst F, Plas E, Fugger R, Fritsch A. Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limbs. Ann. Surg. 220:1 (1994): 86-90.

Shachor D et al. Endoscopic transthoracic sympathectomy in the treatment of primary hyperhidrosis. Arch Surg 129 (1994): 241-244.

Wang L, Hilliges M, Gajecki M, Marcusson J.  Johansson O.  No change in skin innervation in patients with palmar hyperhidrosis treated with tap-water iontophoresis.  Br J Dermatol 131:5 (1994):  742-743.

1993 studies

Kirschbaum C et al. The ‘Trier Social Stress Test’ – a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28: 1-2 (1993): 76-81.

Reinauer S, Neusser A, Schauf G, Holzle E. Iontophoresis with alternating current and direct current offset (AC/DC iontophoresis): a new approach for the treatment of hyperhidrosis. British Journal of Dermatology 129 (1993): 166-169.

Reinauer S, Schauf G, Holzle E. Ross syndrome: treatment of segmental compensatory hyperhidrosis by a modified iontophoretic device. Journal of the American Academy of Dermatology 28:2 (1993): 308-312.

Sato K et al.  Generation and transit pathway of H+ is critical for inhibition of palmar sweating by iontophoresis in water.  J Appl Physiol 75:5 (1993):  2258-2264.

1992 studies

Harlow BL, Cramer DW, Bell DA, Welch WR. Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol. 1992 Jul;80(1):19-26. 

1990 studies

Black M, Gunn A. The management of Frey's syndrome with aluminum chloride hexahydrate antiperspirant. Annals of the Royal College of Surgeons of England 72 (1990): 49-52.

Goh, C. Aluminum chloride hexahydrate versus palmar hyperhidrosis. International Journal of Dermatology 29: 5 (1990): 368-370.

Laccourreye O, Bonan B, Brasnu D, Laccourreye H. Treatment of Frey's syndrome with topical 2% diphemanil methylsulfate (Prantal®): a double-blind evaluation of 15 patients. Laryngoscope 100 (1990): 651-653.

Lillis P, Coleman W. Liposuction for treatment of axillary hyperhidrosis. Dermatologic Clinics 8:3 (1990): 479-482.

Shen J, Lin G, Li W. A new strategy of iontophoresis for hyperhidrosis. Journal of the American Academy of Dermatology 22:2 (1990): 239-241.

1989 studies

Dahl JC, Glent-Madsen L. Treatment of hyperhidrosis manuum by tap water iontophoresis. Acta Derm Venereol 69 (1989): 346-348.  

Sato K, Kang W, Saga K, Sato K.  Biology of sweat glands and their disorders.  I.  Normal sweat gland function.  J Am Acad Dermatol 20 (1989):  537-563.

Sato K et al.  Biology of sweat glands and their disorders.  II. Disorders of sweat gland function.  J Am Acad Dermatol 20:5 (1989):  713-726.

1988 studies

Glent-Madsen L, Dahl JC. Axillary hyperhidrosis: local treatment with aluminum-chloride hexahydrate 25% in absolute ethanol with and without supplementary treatment with triethanolamine. Acta Derm Venereol 68 (1988): 87-89. 

LeWitt P. Hyperhidrosis and hypothermia responsive to oxybutynin. Neurology 38 (1988): 506-507.

1987 studies

Akins D, Meisenheimer J, Dobson R. Efficacy of the drionic unit in the treatment of hyperhidrosis. Journal of the American Academy of Dermatology 16:4 (1987): 828-832.

Dobson R. Treatment of hyperhidrosis. Arch Dermatol 123 (1987): 883-884.

Holzle E, Alberti N. Long-term efficacy and side effects of tap water iontophoresis of palmoplantar hyperhidrosis - the usefulness of home therapy. Dermatologica 175 (1987): 126-135.

James W, Schoomaker E, Rodman O.  Emotional eccrine sweating.  Arch Dermatol 123 (1987):  925-929.

Khurana R.  Orthostatic hypotension-induced autonomic dysreflexia.  Neurology 37 (1987):  1221-1224.

Sato K, Sato F.  Sweat secretion by human axillary apoeccrine sweat gland in vitro.  Am J Physiol 252 (1987):  R181-R187.

Stolman LP. Treatment of excess sweating of the palms by iontophoresis. Arch Dermatol 123 (July 1987): 893-896.

1986 studies

Sloan J, Soltani K. Iontophoresis in dermatology. Journal of the American Academy of Dermatology 15:4 (1986): 671-684.

White JW. Treatment of primary hyperhidrosis. Mayo Clin Proc 61 (1986):  951-956. 

 

1985 studies

Tashjian E, Richter K.  The value of propoxyphene hydrochloride (darvon) for the treatment of hyperhidrosis in the spinal cord injured patient:  an anecdotal experience and case reports.  Paraplegia 23 (1985):  349-353.

1984 studies

Hölzle E, Braun-Falco O. Structural changes in axillary eccrine glands following long-term treatment with aluminum chloride hexahydrate solution. Br J Dermatol 110 (1984):  399-403.

Kuritzky A, Hering R, Goldhammer G, Bechar M.  Clonidine treatment in paroxysmal localized hyperhidrosis.  Arch Neurol 41 (1984):  1210-1211.

1982 studies

Cramer DW, Welch WR, Scully RE, Wojciechowski CA. Ovarian cancer and talc. A case-controlled study. Cancer 50 (1982): 372-376.

Tkach J.  Indomethacin treatment of generalized hyperhidrosis.  J Am Acad Dermatol 6:4 (1982):  545.

1981 studies

Hill, AC, et al. Mechanism of action of iontophoresis in the treatment of palmar hyperhidrosis. Cutis 28 (1981): 69-70,72.  

1980 studies

Levit F. Treatment of hyperhidrosis by tap water iontophoresis. Cutis 26 (August 1980): 192-194.

Rayner C, Ritchie I, Stark G.  Axillary hyperhidrosis, 20% aluminum chloride hexahydrate, and surgery.  British Medical Journal 10:280 (1980):  1168.

1979 studies

Juhlin L, Evers H, Broberg F.  Inhibition of hyperhidrosis by topical application of a local anesthetic composition.  Acta Dermatovener 59:6 (1979):  556-559.

1978 studies

Brandrup F, Larsen P. Axillary hyperhidrosis: local treatment with aluminum chloride hexahydrate 25% in absolute ethanol. Acta Dermatovener (Stockholm) 58 (1978): 461-465.

Hays LL. The Frey syndrome: a review and double blind evaluation of the topical use of a new anticholinergic agent. Laryngoscope 88 (1978): 1796-1824.

Kux M.  Thoracic endoscopic sympathectomy in palmar and axillary hyperhidrosis.  Arch Surg 113:3 (1978):  264-266.  (Abstract Only)

Scholes K et al. Axillary hyperhidrosis treated with alcoholic solution of aluminum chloride hexahydrate. British Medical Journal 2 (1978): 84-85.

1977 studies

Adar R, Kurchin A, Zweig A, Mozes M.  Palmar hyperhidrosis and its surgical treatment:  a report of 100 cases. Ann Surg 186:1 (1977):  34-41. 

 

Shrivastava S, Singh G. Tap water iontophoresis in palmo-plantar hyperhidrosis. British Journal of Dermatology 96 (1977): 189-195.

1976 studies

Bergstresser, P, Quero R. Treatment of hyperhidrosis with topical methenamine. International Journal of Dermatology 15 (1976): 452-455.

1975 studies

Cullen S. Topical methenamine therapy for hyperhidrosis. Arch Dermatol 111 (1975): 1158-1160.

1974 studies

Abell E, Morgan K. The treatment of idiopathic hyperhidrosis by glycopyrronium bromide and tap water iontophoresis. British Journal of Dermatology 91 (1974): 87-91.

1972 studies

Grice K, Sattar H, Baker H. Treatment of idiopathic hyperhidrosis with iontophoresis of tap water and poldine methosulphate. Br. J. Derm. 86 (1972): 72-78.

1971 studies

Frankland J, Seville R. The treatment of hyperhidrosis with topical propantheline - a new technique. Br. J. Derm. 85 (1971): 577-581.

1968 studies

Juhlin L, Hansson H.  Topical glutaraldehyde for plantar hyperhidrosis.  Arch Derm 97 (1968):  327-330.

Levit F. Simple device for treatment of hyperhidrosis by iontophoresis. Arch Derm 98 (1968): 505-507.

 

1951 studies

Bouman HD, Lentzer EM. The treatment of hyperhidrosis of hands and feet with constant current. Am J Phys Med 31 (1952): 158-169. 


Print   Email